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Abstract:  
The mature mammalian urinary system includes the kidneys, ureters, bladder, and 
urethra. The kidneys produce urine that is then carried by the ureters to the bladder where it is 
stored. It is then released through the urethra. In males, the prostate develops at the junction of 
these structures from the prostatic rudiment, the urogenital sinus. Beginning in late gestation, the 
urogenital sinus begins differentiation under the influence of testicular androgens. Continuing 
from birth through puberty, the urogenital sinus grows and differentiates into the adult prostate.  
The urinary system and the prostate share many common properties including their basic 
structure, which consists of an epithelial layer that interacts with fluids, and a stromal smooth 
muscle layer that contracts to propel fluids through the organ. While the origin of the ureter and 
urogenital sinus epithelium are different, the mesenchymal cells that contribute to these 
structures are shared. The T-box transcription factor TBX18 is expressed in these mesenchymal 
cells and beginning at mid-gestation, Tbx18 expressing cells coalesce on the ureter and 
urogenital sinus epithelia, then differentiate into the smooth muscle layer. The loss of Tbx18 
results in deformations and reduced function of the mature organs. 
To study the role of Tbx18 during the formation of ureter and prostate, we utilized a 
hypomorphic allele of Tbx18. This regulatory mutation, referred to as 12Gso, is relatively long-
lived compared with Tbx18-null animals allowing us to assess the long-term impacts of Tbx18 
loss-of-function in the urogenital system. Specifically, 12Gso is a chromosome translocation that 
separates an essential urogenital enhancer from Tbx18. In ureter development, the 12Gso allele is 
able to activate Tbx18 expression but is unable to maintain its expression for the appropriate 
amount of time. This results in a decrease in smooth muscle formation and impedes function of 
the ureter. This same mutation affects the formation of the urogenital sinus mesenchyme where 
Tbx18 cells suffer a similar fate as the ureter; that is, a loss of the prospective smooth muscle. 
Incredibly, the prostate stroma responds by hypertrophy and the adjacent epithelium responds by 
hyperplasia rather than hypotrophy and hypoplasia as occurs in the ureter. Through genome wide 
expression studies and chromatin immunoprecipitation experiments, we found Tbx18 to regulate 
potent cell-cycle effector genes and transcription factor genes oppositely in different cellular 
contexts, providing a partial explanation for Tbx18 loss-of-function phenotypes in these two 
tissues. 
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 Together, this work begins the dissection of the Tbx18 cis-regulatory structure by the 
identification of the ECR1 urogenital enhancer, it establishes the 12Gso mutation as a powerful 
tool in the evaluation of novel and post-natal phenotypes, and this work also provides a causal 
link between the Tbx18 loss-of-function phenotypes in several tissues by implicating Tbx18 in a 
mechanism that maintains proliferation of cells. 
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Introduction:  
It is an astounding idea that a mouse, full in form and function, can develop in the brief 
twenty days of gestation. Much of the complexity rests in the clusters of overlapping 
developmental domains where there are a bewildering number of events that can go wrong 
leading to catastrophe for the forming animal. The fact that so many fertilizations are viable is a 
testament to the resilience of genetic pathways and their interactions. There are still so many 
parts that are not understood. This thesis is an attempt to answer some part of how that can 
happen. To that end, what is the foundational role of Tbx18 in mouse urogenital development? 
How is hypomorphic Tbx18 expression in late gestation likely to impact adult prostate health? 
And finally, what is the greater cellular condition in the urogenital sinus mesenchyme and 
epithelium that responds to depleted Tbx18.  
 
Early Development: 
In the development of the mouse embryo, the three germ layers form at embryonic day 
seven. When these layers are specified, a subset of the intermediate mesoderm migrates ventrally 
into the coelomic cavity of the embryo. Bilaterally, at the level of the forelimb, some of these 
mesodermal cells begin to form the epithelial nephric duct (often referred to as Wolffian Ducts) 
(Davidson 2008). Many of the remaining cells will populate the region surrounding the nephric 
duct as a mesenchyme. As the duct extends caudally, a subset of the adjacent mesenchyme 
induces a budding outgrowth from the nephric duct at the level of the hind limbs around 
embryonic day E10.5. This outgrowth immediately begins branching to become the kidney 
parenchyma and a portion of the ureter. Concurrently to budding, a sliver of adjacent 
mesenchyme located between the nascent kidney branches and nephric duct begins expressing 
the transcriptional repressor Tbx18, which affects a response pathway to differentiate these cells 
into a stromal layer consisting of smooth muscle, fibroblasts, and connective tissue (Airik et al. 
2010; 2006; Bohnenpoll et al. 2013). In addition to the kidney and ureter, these cells will also 
contribute to the bladder, urogenital sinus, and to a smaller degree, to the gonads and adrenal 
glands (Bohnenpoll et al. 2013).  
In the absence of Tbx18, the smooth muscle layer of the ureter forms poorly as do smooth 
muscle layers of the bladder and the prostate (Chapter 2 and 3). In addition to defects in these 
tissues, mice that lack a functional copy of Tbx18 are deaf with vertebral defects and have 
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malformations of the proximal limb bones, in addition to other more subtle conditions (Airik et 
al. 2006; Bussen et al. 2004; Trowe et al. 2008; Cai et al. 2008; Bin Zeng et al. 2011; Grisanti et 
al. 2012). This astounding variety of phenotypes all stem from the loss of one gene. Underlying 
these pleiotropic phenotypes is a developmental program controlled by Tbx18 that facilitates a 
poised condition just before committal to a smooth muscle fate.  
This process and the genes that control it are not well understood. One of the main 
objectives of this work is to understand the regulatory state of the Tbx18-positive mesenchymal 
cells during development. In particular what is the condition of these cells in the urogenital sinus, 
and through which mechanisms can they induce prostate bud neogenesis? In addition, can adult 
prostate health be attenuated when Tbx18 levels are significantly impaired during prostate 
development?  
The large number of tissues and systems affected by Tbx18 ablation suggests a degree of 
complexity in how the gene is expressed. It is reasonable to next imagine a regulatory 
mechanism that controls it with finesse. This regulation is likely to be mediated by a group of 
context dependent transcription factors and cis-acting regulatory element(s) that when combined 
appropriately, confer an extremely specific expression to Tbx18.  
In mammals, cis/trans regulation appears to be complex, frequently including multiple 
transcription factors, co-factors, and histone modifying enzymes binding to and competing for 
relatively small pieces of regulatory DNA. Additionally, there are three- dimensional changes 
that must take place in the chromatin for many of these TF-DNA complexes to interact with 
other regulatory elements such as promoters to modify gene expression. The body of knowledge 
regarding these ideas is growing, but there are still too many conditions and states in the various 
cell types that we remain ignorant of. Piecemeal, developmental domains are being elucidated, 
and the many gene states associated with them. To understand the structure and logic of cis/trans 
regulation will provide deep insights to the nature of gene regulation and the subtle art of 
evolving new expression patterns.  
One of the greatest obstacles to understanding cis-regulation is identifying the regions of 
the genome that act as transcriptional enhancers or silencers. Recent advances in DNA 
sequencing have made it possible to identify all the regions of the genome that a trans-acting 
transcription factor binds. However, many of these regions that TFs bind are either not necessary 
	   
 
 
4 
or redundant. This complicates analysis of their function. Fortunately, there are many ways to 
dissect a locus of regulatory elements that allow us to identify those that are necessary.  
Chromosome translocations represent a significant class of regulatory mutations in most 
breeding populations (Kleinjan and Coutinho 2009; Kleinjan and van Heyningen 1998). They 
occur naturally but can also be induced in the laboratory. When injected with mutagens that 
cause double stranded breaks in DNA, gametogenic cells frequently use Non-Homologous End 
Joining to repair the broken DNA (Elso et al. 2008). Most of these mutations are lethal as NHEJ 
is prone to making small changes in sequence during repair. If those DSBs are in protein coding 
sequence or directly in the binding site of a transcription factor they can cause frame shift 
mutations or prevent TF binding, respectively. Of those cells that survive this assault, many of 
the mutations found are intergenic and now contain a set of chromosome translocations (Elso et 
al. 2013; 2008; Elso 2004). The result is a cis-regulatory structure that is compromised by being 
physically separated onto two new rearranged chromosomes, disconnecting a subset of the cis-
acting elements from their target gene. In the work presented here, we use a mouse mutant with a 
chromosome translocation that disrupts the tissue specific control of a Tbx18 urogenital 
enhancer. The analysis of this mutation, which we refer to as 12Gso, provided insight to the 
location of a urogenital enhancer and thus the initial characterization of the cis-regulatory 
structure of the Tbx18 locus (Chapter 2).  
In this thesis, we begin to dissect the function of Tbx18 in mouse urogenital development. 
The function of Tbx18 in the developing ureter has been partially characterized by others, as well 
as by us (see Chapter 2). But Tbx18 has never been described to have functional importance in 
the development and maintenance of the prostate, which mostly develops post-natally. The work 
entailed by this thesis thus represents the first description of the role Tbx18 performs during the 
development of the mouse prostate (Chapter 3).  
This work was motivated by the following questions. With regard to 12Gso, what is the 
cis-regulatory structure of the Tbx18 locus that regulates its expression in urogenital 
mesenchyme? How do perturbations in Tbx18 regulation, such as that caused by 12Gso, affect 
the downstream function of Tbx18 and what is the phenotypic consequence of these changes? 
How does Tbx18 mis-expression in prostate mesenchyme so profoundly affect development of 
the overlying epithelium? We found that Tbx18 is expressed in a subset of urogenital sinus 
mesenchyme, that Tbx18 positions smooth muscle precursor cells to be receptive of inductive 
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differentiation signals, and that the lack of Tbx18 results not only in reduced smooth muscle of 
the prostate, but also affects the ability of those stromal cells to direct the development and 
maintenance of the prostate epithelium.  
 
Tbx18:  
Loss of somite polarity. 
The T-box Tbx18 was first mapped and cloned from human cells (Yi et al. 1999). Two 
years later the mouse gene was cloned, and in situ hybridizations revealed a very dynamic 
expression pattern (Kraus et al. 2001). Beginning as early as E7.75, expression is observed in the 
pre-somitic mesoderm, a structure that will ultimately form the somites. The somites are 
segmentally repeated units that form the vertebral anlage, and the intermediate and lateral 
mesodermal layers that will become a number of other structures including visceral stroma, 
bone, adipose, muscle, and various forms of connective tissue. As the somites begin budding 
from the pre-somitic mesoderm, Tbx18 expression persists in the anterior portion of each somite. 
In the absence of Tbx18, mutant mice develop severely malformed axial skeletons: the 
prospective vertebral pedicles lose their boundary identity prior to ossification and migrate into 
adjacent regions producing vertebrae that grow together and fuse. This fusion results from lost 
Tbx18 repression of Uncx4.1 in the anterior somite half. Uncx4.1 specifies the posterior, and 
probably represses Tbx18 in that portion. When Tbx18 is not present, transcriptional up-
regulation of Uncx4.1 occurs in the anterior somite with concomitant loss of anterior identity. 
The anterior half then ossifies in a manner similar to the Uncx4.1 regulated ossification of the 
posterior half (Farin et al. 2008; Bussen et al. 2004).  
This observation suggests a state where Tbx18 is essential to maintain a cellular condition 
that resists immigration by adjacent cell types and prepares the cells for forthcoming ossification 
events. Much of this property is mediated through Delta-Notch signaling between Tbx18-positive 
anterior somites and the Tbx18-negative posterior somites. The mouse homolog of Delta, Dll1 is 
expressed in the pre-somitic mesoderm, but as somites bud, Tbx18 is up-regulated in the anterior 
somite where it represses Dll1. Indeed, anterior-posterior somite polarity is established by Delta-
Notch signaling concurrent with Tbx18 expression in the nascent somites, but AP polarity is not 
dependent on Tbx18. This theme is common to many tissues where Tbx18 is expressed, 
suggesting a possible mechanism by which it acts.  
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Reduced smooth muscle formation in the ureter.  
Tbx18 is expressed in many parts of the developing urogenital system. At E9.5 Tbx18 
mRNA is first detected in the urogenital ridge, which is largely derived from the intermediate 
mesoderm. Its expression pattern forms at the boundary between the nephric duct (Wolffian) and 
the coelomic epithelium. By E11.5 the mRNA is detected in a band of loose mesenchyme that 
extends from just below the heart, down into the lower abdominal cavity where it meets the 
cloaca (Airik et al. 2006; Kraus et al. 2001). At this same stage, the first steps of kidney 
development are underway. As the kidney develops, Tbx18-positive cells migrate onto the 
ureteric bud stem, which is differentiating into the proximal portion of the ureter. The nephric 
duct between the ureteric bud and the cloaca becomes the distal portion of the ureter. Through 
the remainder of gestation, Tbx18 continues to be detected in differentiating smooth muscle cells 
adjacent to the ureter epithelium. Just before birth, Tbx18 is down-regulated in the ureter by a 
feedback mechanism controlled by the smooth muscle driver, Myocd. In the absence of Tbx18, 
the proximal ureter smooth muscle is poorly formed. There are reduced numbers of smooth 
muscle cells that are also disorganized. The ureter epithelium is disorganized as well with 
reduced cell numbers and reduced elasticity. While the smooth muscle of the upper urinary 
system is down-regulating Tbx18, the T-box gene continues to be expressed in the lower 
urogenital tract (Airik et al. 2006; 2010; Bohnenpoll et al. 2013; Kraus et al. 2001).  
The genetic control of smooth muscle formation in the ureter is beginning to be 
illuminated. Within the undifferentiated ureter mesenchyme, Tbx18 activates Sox9. The ECM 
that surrounds the ureter epithelium is modified by Sox9 targets, including Col2a1, Vcan, and 
Thbs1. The deposition of these ECM components then signals to the surrounding mesenchyme 
that condensation should begin (Airik et al. 2010; Kent et al. 1996). In the ureter epithelium, 
canonical Wnt7b signaling through Fzd1 instructs the mesenchyme to continue proliferating and 
for the cells closest to the ureter to differentiate into smooth muscle cells, while the more distal 
cells default to a fibroblast differentiation pathway, or into an apoptosis pathway (Trowe et al. 
2012). Interference with most of these pathways produces a similar disorganization of the ureter 
epithelium and smooth muscle layer (Airik et al. 2010; Trowe et al. 2012; Nie et al. 2010; 2011). 
In Tbx18-null mutants, Sox9 expression is prematurely lost in the ureteric mesenchyme, 
indicating that Tbx18 is necessary to activate Sox9 in the mesenchyme, and indirectly promote 
the production of instructional ECM components. Interestingly, when only Sox9 is ablated in the 
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ureter mesenchyme, the ureter epithelium develops normally which is not the case in Tbx18-null 
animals. One interpretation of this result is that Sox9 and Tbx18 co-expression in the 
mesenchyme influences a pathway in the epithelium, but that Sox9 also acts independently of 
Tbx18 to influence epithelial differentiation. Furthermore in the mesenchyme, Tbx18 and Sox9 
interact genetically to promote proliferation and differentiation of the mesenchyme. Together 
these results implicate an indirect mechanism by which Tbx18 influences Sox9 to control 
epithelial development, but in a manner that is spatially and temporally separated - possibly 
through some diffusible factor. These pathways converge on Myocd to initiate smooth muscle 
differentiation, when appropriate.  
Six1 is the mouse homolog of the Drosophila Sine Oculis homeobox with an essential 
role in the branching morphogenesis of the kidney and proliferation of the ureter stroma (Nie et 
al. 2011; 2010). In mouse, this gene has been shown to interact with Tbx18 at the genetic and 
protein level to regulate downstream target genes. The primary phenotype in mice that are 
heterozygous for both alleles is failure of stromal proliferation. The smooth muscle pathway is 
insufficiently activated in Tbx18+/-; Six1+/- mesenchyme, and these cells default to apoptosis, 
resulting in significantly reduced numbers of SMCs in the ureter. These mice also have a 
secondary phenotype similar to Tbx18-/- animals, in that the ureter epithelium fails to proliferate 
and differentiate appropriately. The mechanism by which this is mediated is still unclear. 
Suspected ureter epithelium effectors include Shh and Wnt7b. In Tbx18+/-; Six1+/-, Shh is 
significantly reduced in the ureter epithelium as well as the Ptch1 receptor for Shh in the 
condensing mesenchyme. Although Six1 is expressed in the ureter epithelium, it is activated in 
this layer after Shh expression, when morphological differences are already apparent. Again 
these data implicate an upstream mechanism whereby Tbx18 activates a diffusible factor in the 
mesenchyme, which then up-regulates Shh in the epithelium, and the signal is reciprocated to the 
mesenchyme via Wnt7b and Shh.  
The other factor known to interact with Tbx18 is β-Catenin. In the prospective 
mesenchyme, Ctnnb1 stabilizes the expression of Tbx18. In a set of experiments where Ctnnb1 
mutants with no degradation signal are driven in the urogenital mesenchyme, Tbx18 levels 
persist longer than normal. These cells have increased proliferation and decreased apoptosis. The 
main finding of this study is that stabilization of Ctnnb1 and therefore Tbx18 produces an 
increase of smooth muscle cells. The excess of additional SMCs comes from the precursor 
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mesenchymal population at the expense of the fibroblast pathway (Trowe et al. 2012). This 
finding is interesting because it provides a causal link between the epithelial expressed Wnt7b 
and the Fzd1 expression in the condensing mesenchyme. Overexpression of Wnt7b presumably 
would produce a similar phenotype, although that experiment has yet to be conducted.  
 
Physical Interactions.  
There have been two different methods by which TBX18 is thought to interact with other 
proteins. The first, which appears to be common to all T-box proteins, is the ability of TBX18 to 
heterodimerize and homodimerize with other T-box proteins and itself, respectively. 
Specifically, TBX18 has been shown to heterodimerize with TBX15 and TBX20 (Farin et al. 
2007; Kaltenbrun et al. 2013). Interestingly, the dimerization with TBX15 takes place in the 
cytoplasm. Here, TBX18 forms strong homodimers with itself through its T-box domain. To a 
slightly lesser degree, TBX18 heterodimerizes with the closely related TBX15, but appears to be  
incapable of dimerizing with the more distantly related T (Brachyury) protein. This provides a 
possible mechanism for the regulation of subcellular localization of T-box proteins.  
Multiple studies have evaluated the T-box genes for nuclear import and export signals. 
All T-box proteins have been shown to contain at least a putative Nuclear Localization Signal 
(NLS) (Farin et al. 2007; Kulisz and Simon 2008). Most of these have been shown to be 
necessary for nuclear import, but one confounding property of many T-box proteins is that they 
are not always located in the nucleus. For example, we have observed TBX18 localization to 
vary greatly depending on the cell type. In tissue culture, TBX18 is observed in both the nucleus 
and cytoplasm of C2C12 myoblasts, but in the mesonephric M15 cells, expression is entirely 
nuclear. In vivo, most cells within the embryo appear to localize TBX18 into the cytoplasm with 
only a subset of cells displaying nuclear localization of the protein. Reasons for this are currently 
unclear. One hypothesis is that since many T-box proteins contain a NLS in the T-box domain, 
they may hetero and homodimerize in the cytoplasm to limit accessibility of the nuclear import 
machinery to the NLS. TBX15 and TBX18 heterodimerize through their T-box domains in the 
cytoplasm. TBX18 does not contain a NLS in its T-domain, but TBX15 does. This may explain 
why we see differential localization of TBX18 in different cell types; nuclear exclusion by 
interaction with other T-box proteins.  
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In addition to the ability to interact with other T-box transcription factors, TBX18 
contains an Engrailed homology domain that facilitates a repressor activity through an 
interaction with Groucho-related genes (Grg). GRG proteins recruit histone de-acetlyases to 
gene promoters to compact chromatin and consequently reduce expression of the relevant gene 
(Jennings and Ish-Horowicz 2008). Using co-immunoprecipitation, TBX18 was shown to 
interact with TLE3 (Transducin-Like Enhancer of split 3, the human orthologue of mouse Grg3) 
in HEK293 cells. In Xenopus embryo hearts, TBX18 protein co-precipitates with TBX20, as 
well as an entire Groucho repressor complex and the NuRD Nucleosome Remodeling and 
Deactelyase complex (Kulisz and Simon 2008). The eh1 domain found in TBX18 is conserved 
across vertebrates (Farin et al. 2007). To complicate matters, a few T-box TFs have been shown 
to switch from activators to repressor, and vice versa, through interaction with Groucho co-
repressors (Kawamura et al. 2008). This range of possible interactions hugely expands the 
possible transcriptional effects TBX18 and other T-box proteins can have on their target genes. 
TBX18 may function as a transcriptional activator as well, but the manner in which it was tested 
for repressor activity is not capable of demonstrating this.  
 
Malformations of the prostate.  
The prostate is a mammalian reproductive organ that is mostly composed of ectodermal 
derived epithelium and mesoderm derived stroma. It rests at the junction between the urethra and 
the bladder, also where the seminal vesicles, ureter, and vas deferens congregate. In humans, the 
prostate is a single globe that encompasses the urethra passing through it. In mice, roughly the 
same internal organization exists, but it lacks the encapsulating connective tissue of humans, so 
each lobe is freely suspended in the abdomen. In both species the prostate functions in sexual 
climax where it contributes a variety of factors and most of the fluid of the ejaculate. This organ 
is especially prone to overgrowth pathologies, including cancers. Because of its high tendency to 
develop cancer, many researchers have focused their efforts on genes and stages that are directly 
related to disease development. However, as with other systems, it is becoming increasingly 
apparent how important development can be for the long-term health of the organ, and therefore 
the individual (Powers and Marker 2013)  
 A longstanding problem to the study of prostate development is the lack of genetic 
models for stroma-specific genes. There are many mouse models for genes expressed in the 
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epithelium, as well as some that are specific to the stromal side but at later stages in 
development. The two earliest marker genes are Sox9 and Nkx3-1, but both of these are 
expressed in the urogenital sinus epithelium (Sciavolino et al. 1997; Bieberich et al. 1996; 
Thomsen et al. 2008; Huang et al. 2012). Tbx18 represents one of the earliest known markers for 
urogenital mesenchyme, indicating a pool of smooth muscle precursor cells in the urogenital 
sinus mesenchyme as early as E12.5, which is prior to cloacal septation to form the bladder and 
UGS. Additionally, many of the global null alleles are embryonic lethal due to their roles in other 
tissues. These models preclude the study of long-term effects from developmental changes. To 
address this, we used the relatively long-lived 12Gso mutant to study the adult condition 
resulting from developmental mis-regulation of Tbx18.  
In this work (Chapter 3), we demonstrate for the first time that Tbx18-positive cells 
contribute to the prostate stroma. Primarily, they contribute to the ventral prostate stroma where 
Tbx18 regulates a number genetic pathways, including those required for smooth muscle 
formation as well as signaling mechanisms that indirectly control epithelial development. In 
12Gso/Tbx18- compound heterozygotes, Tbx18 expression is significantly reduced but not 
ablated, giving rise to a ventral prostate stroma that displays hypertrophic smooth muscle and 
severely disorganized epithelium. This demonstrates the vital role of Tbx18 in the specification 
of the prostate stromal smooth muscle, but importantly, that the pool of Tbx18 mesenchymal 
cells function to regulate the differentiation and proliferation of the prostate epithelium. These 
findings may assist in the discovery of stromal signals that permit epithelial overgrowth and 
eventual prostate pathologies to form.  
 
The Tbx18 Locus and Cis-Regulation. 
The highly dynamic expression pattern of Tbx18 implicates a complex regulatory 
mechanism for the gene. One way that gene expression patterns are controlled is through a 
collection of cis-acting regulatory elements that are bound by trans-acting transcription factor 
complexes. In fact, it is a property common to many developmental regulators, such as Tbx18, to 
have a collection of enhancer and silencer elements dispersed around the gene locus (Nobrega et 
al. 2003; Ovcharenko et al. 2005). It is through these arrays of regulatory elements that upstream 
TFs act to control target gene expression. The Tbx18 gene sits in a region roughly 1Mbp in size 
that is highly conserved in sequence, and structure over roughly 75 million years that separate 
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humans and mice. One possible explanation for why this may be true is that there is a collection 
of cis-acting elements that are dispersed around Tbx18, and the position and orientation of those 
elements are essential to ensuring the proper expression of Tbx18 in space, time, and amount.  
Recent work has shown that a subset of the Tbx18 regulatory structure is located within a 
210 kbp region around the gene (Wang et al. 2009). In this study, they used a Bacterial Artificial 
Chromosome (BAC) that includes the Tbx18 gene in the context of the surrounding genomic 
material. This region of the locus is shown to drive the expression of Tbx18 in most tissues, 
including the urogenital system in a manner very similar to native expression. These data suggest 
that this 210 kbp region contains urogenital, whisker, limb, heart, and some (but not all) somite 
enhancers (Wang et al. 2009). This work assisted us in the discovery of a urogenital enhancer, 
which we call ECR1, that drives expression of a reporter gene in the same manner as native 
Tbx18 (Chapter 2). Using chromatin immunoprecipitation, we show that SOX9, PAX2, and 
WT1, all of which are essential to the development and sensitivity of the urogenital 
mesenchyme, bind this enhancer.  
Because 12Gso mutants express a clear urogenital phenotype, we hypothesize that ECR1 
activity is essential to proper Tbx18 expression, and thus to early differentiation of mesenchymal 
cells in the ureter, prostate and potentially, other urogenital tissues. With interest in beginning to 
construct a more accurate representation of the larger Tbx18 regulatory network, we have also 
focused on determining downstream targets for the T- box protein in mesenchymal and 
specifically, prostate cells. Additionally, these factors bind within the Tbx18 promoter region 
implicating these factors in the direct regulation of Tbx18 in the development of the urogenital 
system.  
 
12Gso and ECR1.  
The Tbx18 BAC study was particularly interesting to us because of the region the reporter 
BAC covers. On the 3’ end of Tbx18 (the centromeric side) the BAC extends about 78kbp; this 
intrigued us because the 12Gso translocation breaks very near the BAC end. When we evaluated 
the urogenital expression domains included in the BAC study and the abnormal phenotypes of 
our mutant, we noticed considerable tissue overlap. This then led us to the discovery of a Tbx18 
enhancer in the distal end of the region spanned by the BAC, which functions in the urogenital 
system. This enhancer is the first to be identified for Tbx18 and one of the first to be described 
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for any mammalian T-box gene. As discussed in Chapter 2, this enhancer is likely to be only one 
of several that control Tbx18 expression. Work is currently underway to identify additional 
regulatory elements for Tbx18 with activity in the urogenital sinus.  
The primary benefit of the 12Gso mutation is that since it is a regulatory mutation, it does 
not ablate Tbx18 expression in all tissues. Global loss of Tbx18 is embryonic lethal in mice. 
Differing from null mutants, many 12Gso homozygotes and 12Gso/Tbx18- compound 
heterozygotes are able to survive into adulthood. This gives us the ability to determine the 
resulting phenotype of reduced Tbx18 expression in the development of organs that complete 
development post-natally, including the prostate. We have shown that TBX18 activity persists in 
many mesenchymal cell types during postnatal stages, and that the mis-expression of this protein 
may have undiscovered roles in phenotypes with significance to human health. With this 
valuable mutant in hand, as well as Tbx18 knock-out, knock-in, and conditional (floxed) alleles 
provided by our collaborators, we are in an excellent position to discover these novel 
phenotypes.  
Tbx18 regulates the development of urogenital smooth muscle from an undifferentiated 
mesenchyme. This much is clear. What we do not understand is what this transcription factor 
does to produce this result. Surely, Tbx18 does not act alone, it must rely on other factors to 
precipitate the differentiation into smooth muscle. But what property does Tbx18 confer to the 
state of these cells that allows them to differentiate in this context? What is so unique to that 
environment? Additionally, how does a reduction in Tbx18 expression result in the abnormal 
development reported here? These questions stemmed from the discovery of the 12Gso mutation, 
and the phenotypes that result from it. In some way this distant alteration disturbs the mechanism 
that TBX18 controls in the context of urogenital development. It is a peculiar property that 
distant pieces of apparently nonfunctional DNA, can have such a significant impact on the local 
gene activity. But accumulating data suggest they do.  
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Abstract: 
 The vertebrate T-box transcription factor gene Tbx18 performs a vital role in 
development of multiple organ systems. Tbx18 insufficiency manifests as recessive phenotypes 
in the upper urinary system, cardiac venous pole, inner ear, and axial skeleton; homozygous null 
mutant animals die perinatally. Here, we report a new regulatory mutation of Tbx18, a reciprocal 
translocation breaking 78 kbp downstream of the gene. 12Gso homozygotes present urinary and 
vertebral defects very similar to those associated with Tbx18-null mutations, but 12Gso is clearly 
not a global null allele since homozygotes survive into adulthood. We show that 12Gso down-
regulates Tbx18 expression in a manner that is both spatially- and temporally-specific; combined 
with other data, the mutation points particularly to the presence of an essential urogenital 
enhancer located near the translocation breakpoint site. In support of this hypothesis, we identify 
a distal enhancer element, ECR1, which is active in developing urogenital and other tissues; we 
propose that disruption of this element leads to premature loss of Tbx18 function in 12Gso 
mutant mice. These data reveal a long-range regulatory architecture extending far downstream 
ofTbx18, identify a novel and likely essential urogenital enhancer, and introduce a new tool for 
dissecting postnatal phenotypes associated with dysregulation of Tbx18. 
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Introduction: 
  Tbx18 is a member of the ancient T-box gene family, encoding a transcription factor with 
critical roles in the development of the ureter, heart, inner ear, and somites (Airik et al. 2006; 
Bussen et al. 2004; Christoffels 2006; Trowe et al. 2008). Tbx18-null mutant animals display 
recessive malformations of the axial skeleton, reflecting the gene’s important role in 
maintenance of anterior-posterior identity in the developing somites (Bussen et al. 2004; Farin et 
al. 2008). Newborn Tbx18-/- mice and late-stage embryos also display hydronephrosis and 
hydroureter, resulting from incomplete and irregular formation of the smooth muscle layer of the 
ureter required for proper functioning (Airik et al. 2010; 2006; Nie et al. 2010). The homozygous 
mutant animals also display complex abnormalities of the heart (Christoffels 2006; Wiese et al. 
2009). These animals die soon after birth with signs of respiratory distress implicating their 
severely malformed thoracic skeletons (Bussen et al. 2004; Christoffels 2006). This suite of 
severe developmental phenotypes reflects the importance of Tbx18 expression during multiple 
developmental time points, and in a diverse range of tissues. 
  Tbx18 expression is first detected in presomitic mesoderm at embryonic day 7.75 (E7.75) 
of mouse development, and later appears in the urogenital ridge, the proepicardium of the heart, 
limb buds, dermis, otic mesenchyme, and other tissues (Bin Zeng et al. 2011; Bohnenpoll et al. 
2013; Grisanti et al. 2012; Kraus et al. 2001; Trowe et al. 2008). This dynamic pattern of tissue-
specific expression suggests the existence of complex gene regulatory mechanisms involving 
multiple tissue- and stage-specific enhancers. Supporting this idea, Tbx18 is embedded in a 
“gene desert” region, which is highly conserved from mouse to human, with nearest upstream 
and downstream neighbors residing more than 500 kbp away. Genomic neighborhoods like this 
one are found primarily around genes which, like Tbx18, encode developmental regulators with 
dynamic patterns of spatial and temporal expression (Ovcharenko et al. 2005). These extended 
gene deserts house multiple enhancers and silencing elements that interact through long-range 
chromatin loops; mutations that disrupt the structure of such domains can alter or ablate gene 
expression, even when they occur long distances away from the gene. Mutations like these, 
primarily in the form of reciprocal translocations, have revealed the existence of distant 
regulatory elements that would have been difficult to identify by other means. For example, 
translocations and deletions located in a region extending more than 1 Mbp upstream of Sox9 
have been linked to campomelic dysplasia; the more distant translocations yield phenotypes that 
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recapitulate only subsets of the disease phenotypes indicating tissue-specific disruption of the 
gene (Gordon et al. 2009). Translocations associated with Pax6, Shh and other important 
developmental regulators have also been crucial to the discovery of regulatory elements for those 
genes (Kleinjan and Coutinho 2009; Lettice 2003). 
  The structure of the Tbx18 gene desert locus suggests that this gene could also be 
regulated by a system of long-range enhancers. In one recent study, a bacterial artificial 
chromosome (BAC) reporter construct was shown to recapitulate most but not all aspects of the 
Tbx18 expression pattern; these data indicated that most of the important regulatory sequences 
would be found within an approximately 209 kbp region surrounding the gene (Wang et al. 
2009). However, beyond this study, very little is known about the organization and function of 
the regulatory elements directing the complex developmental expression patterns of Tbx18 or 
other members of the extended T-box transcription factor family. 
  Here, we report the molecular and phenotypic characterization of a mouse mutation, 
12Gso, a T(4;9) reciprocal translocation corresponding to a clean breakage-and-reunion event 
located 78 kbp downstream of Tbx18. 12Gso homozygotes display ureter and axial skeleton 
abnormalities very similar to those seen in Tbx18-/- mice, and complementation tests confirm that 
these recessive phenotypes are due to Tbx18 loss-of-function. The translocation breaks within a 
cluster of highly conserved sequences roughly 4.5 kbp in length, and a transgenic reporter assay 
confirms that sequences surrounding the breakpoint site contain at least one enhancer that is 
active in the urogenital mesenchyme. The 12Gso ureter phenotype and Tbx18 gene expression 
pattern strongly suggests that this downstream enhancer region is required in cis to activate the 
Tbx18 promoter during critical stages of urogenital development. Our data also indicate that 
additional enhancer(s) essential to somite development will be found further downstream of the 
gene. These data provide new insight to the Tbx18 regulatory structure, identify a novel 
developmental enhancer region that directs expression of a reporter in the urogenital 
mesenchyme, and define 12Gso as a novel regulatory mutation of Tbx18. 
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Results: 
Basic characterization of 12Gso mutants. 
  The 12Gso mutation arose in the offspring of male mice treated with bis-acrylamide in 
late meiotic stages, a treatment known to generate translocations at high frequencies (reviewed in 
(Culiat et al. 1997). The founder animal and its offspring were identified as translocation carriers 
by breeding tests, which revealed semi-sterility; this identification was confirmed by analysis of 
Giemsa-stained metaphase chromosomes, which revealed that the animals carried a reciprocal 
translocation affecting chromosome 4 (chr4) band B2 and chr9, band E2 (Chittenden 2002). 
Heterozygous 12Gso animals are fertile and long-lived with no apparent phenotype other than 
translocation-related semi-sterility. However, homozygous 12Gso animals were found to display 
abnormalities of the axial skeleton including vertebral fusion, leading to a significant shortening 
of the body and often a kinked tail, as well as bifid ribs (Figure 2.1D,I,N). Upon closer 
inspection, we observed kidney pathologies including increased kidney size, hydroureter and 
early stages of hydronephrosis at birth (Figure 2.1S,X). Hydronephrosis and hydroureter was 
fully penetrant in both kidneys in all animals of both genders, although the severity at birth 
varied by individual. In adults the hydronephrosis was more severe, distending the entirety of the 
kidney and proximal ureter. While some 12Gso homozygotes survive well past weaning (Figure 
2.2), many animals die as juveniles and some within a few days of birth. These phenotypes 
indicated that the mutation disrupted the function of a gene that is critical in the development of 
the somites and urinary system, and possibly other tissues. 
  
Mapping and sequencing the mutation. 
  The 12Gso chr4 breakpoint had previously been mapped to a region spanned by a single 
bacterial artificial chromosome (BAC) clone, RP23-353g1, with fluorescent in situ hybridization 
(FISH). The translocation breakpoint was shown to disrupt the Abca1 gene, which spans most of 
the BAC region, and was further localized to a 476 bp region corresponding to intron 34 of the 
gene (Chittenden 2002). We designed primers within the 3’ edge of exon 34 and the 5’ edge of 
exon 35 region to isolate T(4;9) and T(9;4) junction fragments from 12Gso mutant DNA by 
“genome walking” (see (Chittenden 2002) for details). We sequenced the junction fragments and 
then designed primers flanking the chr9 breakpoint region to sequence DNA surrounding the 
12Gso mutation sites on both chromosomes and compared them to wild type DNA. The results 
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indicated that the mutation occurred as a clean breakage-and-reunion event (Figure 2.3A) very 
similar to those documented in the analysis of other germline translocations (Elso et al. 2013; 
2008; Elso 2004). 
  The chr9 breakpoint is within a large “gene desert” region, located approximately 78 kbp 
downstream of Tbx18 (105 kbp from the annotated Tbx18 promoter; Figure 2.3B). Because of 
the striking similarities between the 12Gso phenotype and the skeletal and kidney abnormalities 
observed in Tbx18-null mutant mice (Airik et al. 2006; Bussen et al. 2004), we hypothesized that 
the 12Gso mutation disrupts Tbx18 expression in those tissues.  
 
Complementation tests confirm that 12Gso is an allele of Tbx18. 
  To test the relationship between 12Gso, Abca1 and Tbx18, we used targeted null 
mutations that are available for both genes (Bussen et al. 2004; Christiansen-Weber et al. 2010). 
Abca1 encodes a lipid transporter gene that plays an important role in cholesterol metabolism in 
both humans and mice, but Abca1-/- mice are long-lived and relatively healthy, with no recorded 
defects of the axial skeleton or ureter (Christiansen-Weber et al. 2010). We crossed Abca1-/+ 
with 12Gso/+ animals to generate several litters containing compound 12Gso/Abca1- mice. All of 
the compound animals (n=10) were born with normal skeletons and no apparent urinary defects 
when sacrificed at 0 days post-natal (Figure 2.1C,H,M,R,W). 
  On the other hand, crosses between Tbx18-/+ and 12Gso/+ mice generated compound 
mutants (12Gso/Tbx18-) with skeletal defects, including fused vertebrae, bifid ribs and 
hydroureter with concomitant hydronephrosis that are typical of the recessive defects associated 
with each mutation (Figure 2.1E,J,O,T,Y). We genotyped all pups born from these crosses, and 
all compound mutants (19 of 60 animals genotyped) but none of the carriers or wild type 
littermates (41/60) displayed the somite and kidney defects. These data confirm that 12Gso is a 
loss-of-function allele of Tbx18, affecting gene function in both somite and urinary development. 
On the genetic background we used for this study (see Methods), the axial skeleton 
phenotype associated with Tbx18-/- was less severe than has previously been reported (Figure 
2.1S)(Bussen et al. 2004). On this background, we observed that 12Gso homozygous mutants 
and Tbx18-/- skeletons were very similar, and equally malformed (Figure 2.1). 
In contrast to Tbx18-null mutants (Bussen et al. 2004), 12Gso animals can survive well 
into adulthood, and some 12Gso/Tbx18- compound mutants also share this relative longevity 
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(Figure 2.2). This fact suggests that Tbx18 expression is only partially abrogated by the 12Gso 
translocation, suggesting that the mutation is either a global hypomorph (with lower levels of 
expression in all tissues) or that the mutation affects Tbx18 expression only in specific tissues or 
at certain developmental time points or some combination of both possibilities. 
 
Tbx18 expression is significantly down-regulated in 12Gso mice. 
  To examine Tbx18 expression, we collected 12Gso and Tbx18 heterozygotes, 
12Gso/Tbx18- compound heterozygotes, and wild type littermates at different embryonic stages. 
First, we isolated RNA from whole embryos collected at embryonic day 10.5 (E10.5) and E11.5 
and performed quantitative RT-PCR (qRT-PCR) to measure and compare overall levels of Tbx18 
expression. Tbx18 mRNA levels are reduced by 12Gso at these stages but not entirely lost 
(Figure 2.4A). 12Gso and Tbx18 heterozygotes showed a roughly 40% reduction in Tbx18 
mRNA quantities at E10.5, but no significant change at E11.5. 12Gso/Tbx18- compound 
heterozygotes were significantly down-regulated compared to wild type mice and heterozygotes 
at these stages. At E12.5, we dissected embryo heads, upper torsos, lower torsos, and limbs. 
Tbx18 was reliably detected in the wild type embryos of each stage as well as in all of the 
dissected tissue samples we tested. Compared to wild type littermates, we found Tbx18 to be 
significantly down-regulated in heads, upper torsos, and lower torsos, but not changed in the 
limbs of the compound heterozygotes where Tbx18 expression is particularly high at this 
developmental stage (Kraus et al. 2001)(Figure 2.4A). 
  To examine protein expression at the cellular level, we generated a polyclonal antibody to 
a unique epitope of the protein (see Methods) and carried out immunohistochemistry (IHC) in 
sectioned E12.5, E13.5, and E15.5 mutant and wild type embryos (Figure 2.4B-G). Because 
12Gso mutants display a clear ureter phenotype, we focused primarily on expression in that 
tissue. In addition, we tested expression of the SOX9 protein at these stages (Figure 2.4B’-G’). 
Sox9 has been shown to act downstream of Tbx18 in the ureteric mesenchyme; the loss of 
TBX18 in the condensing mesenchyme results in the loss of Sox9 gene expression and animals 
inheriting a Tbx18+/Cre,Sox9flox/flox genotype present extreme hydroureter (Airik et al. 2010). 
SOX9 thus provides an important and relevant marker for this tissue during this period of 
embryonic development. 
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We detected significant levels TBX18 protein in the mesenchyme surrounding the ureter 
epithelium in both compound mutant and wild type embryos at E12.5 (Figure 2.4B,C; dashed 
lines encircle ureter epithelium in all panels). However, clear differences were detected between 
mutant and wild type littermates by E13.5.  
At this stage in wild type animals, TBX18 protein was detected in the nuclei of cells 
concentrated in the inner ring of condensing mesenchyme adjacent to the epithelium (Figure 
2.4D). In striking contrast, TBX18-expressing cells were significantly reduced in number, and 
primarily limited to the distal perimeter of mutant ureters (arrows in Figure 2.4E); with a few 
isolated cells located in the mesenchyme proximal to the ureter epithelium. By E15.5 TBX18 
protein was not detected in the developing ureter of either genotype, consistent with the reported 
down-regulation of the gene in this location (Airik et al. 2006)(Figure 2.4F,G).  At the earlier 
stages SOX9 was detected in scattered cells in the ureter epithelium and the mesenchyme 
consistent with previous reports (Airik et al. 2010)(Figure 2.4B’ with arrows). We detected no 
obvious differences in SOX9 expression in the 13.5 mutant ureters despite the premature loss of 
TBX18 (Figure 2.4B’-E’).  Indeed, SOX9 expression was still robust in both epithelial and 
mesenchymal compartments at E15.5 in both wild type and mutant mice (Figure 2.4F’,G’). At 
these stages and in this tissue at least, 12Gso thus appears to have little if any effect on 
expression of the Sox9 gene.  
Taken together, the qRT-PCR and IHC expression data indicate that the 12Gso mutation 
has both spatial (tissue-specific) and temporal (developmental stage-specific) effects on Tbx18 
expression. 
 
Generating a Tbx18 enhancer reporter construct. 
  Mapping, complementation and expression results suggested that the 12Gso mutation 
separates Tbx18 from critical downstream enhancers that are required for appropriate function in 
somites and ureteric mesenchyme, and perhaps other tissues. Theoretically at least, these putative 
enhancers could be located anywhere within the 475 kbp between Tbx18 and the nearest 
neighboring gene, 4922501C03Rik, or possibly even further downstream of the gene. However, 
recent data made it likely that we would find a critical enhancer element much closer to the 
breakpoint site. In particular, a 209 kbp BAC reporter containing Tbx18 coding sequences has 
been shown to recapitulate much of the normal pattern of embryonic and neonatal expression 
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displayed by the native Tbx18 gene (Wang et al. 2009). This BAC clone, RP23-353o7, contains 
and extends just past the 12Gso breakpoint sequence (Figure 2.3B).  
 Since the 12Gso mutation is associated with clear somite and ureter phenotypes, we 
hypothesized that enhancer(s) active in one or both of these tissues would be found in the region 
directly surrounding the 12Gso breakpoint site. However, given that the RP23-353o7 reporter 
faithfully recapitulates Tbx18 urogenital tissue but not in anterior somites (Wang et al., 2009), 
this region seemed particularly likely to harbor elements active in urogenital tissues. Therefore, 
we focused on a 4.5 kbp region spanning the mutation site, and extending to the end of the region 
spanned by RP23-353o7 (chr9:87624100-87628673 in the Mm10 genome sequence build); we 
will hereafter refer to this sequence as ECR1. ECR1 includes several subregions that are highly 
conserved in mammals; the 12Gso breakpoint interrupts one of these conserved genomic regions 
(Figure 2.3C). The breakpoint falls between two clusters of transcription factor binding sites 
(TFBS) that are conserved in the mouse, human, and bovine genomes; 12Gso thus separates 
these two closely apposed TFBS clusters. On the distal side of the breakpoint lies motifs for 
ALX4, LEF1, and Myogenin, E2A and LBP1 – (the latter three proteins recognizing the same E-
box like conserved motif (CAGCTG)). About 140 bp away, but on the Tbx18-proximal side of 
the 12Gso mutation, lies a conserved EVI1 motif and sites for GATA protein binding adjacent to 
or overlapping the shared binding sites for FOXO proteins (FOXO1,2, and 4), SRY (all 
including TAAACA) (Figure 2.3C). The homologous human region (chr6:85350507-85351466 
in the hg19 genome build) contains a peak of DNAse hypersensitivity but has not been identified 
as a binding site for any of the transcription factors thus far tested with ChIP in human or mouse 
cells by the ENCODE consortium (not shown). 
We PCR amplified and cloned the ECR1 sequence into an Hsp68 promoter-LacZ reporter 
plasmid (Kothary et al. 1988; Nobrega et al. 2003) and injected the construct into mouse 
embryos to generate transgenic lines. We collected embryos from multiple transgenic lines, 
testing ß-galactosidase (ß-gal) staining in whole mount preparations. Very similar patterns of 
expression were detected in five independent lines; we used the most intensely active transgenic 
line ECR1-2870 for in-depth analysis of developmental expression. 
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ECR1 drives reporter expression in urogenital and other tissues. 
  We collected transgenic embryos carrying the ECR1 reporter at multiple stages of 
development and utilized the LacZ transgene to detect tissue specificity of the ECR by staining 
embryos or isolated tissues as whole-mount preparations or generating frozen sections for ß-gal 
staining (see Methods). ECR1-transgenic embryos consistently showed strong ß-gal activity in 
urogenital tissues. Spatial expression was consistent with known domains of native Tbx18 
expression, although in many cases the timing of expression during development was not entirely 
consistent with the native expression of Tbx18. For example, ECR1 staining in the ureter persists 
through birth (not shown) while the Tbx18 mRNA is depleted at this stage (Figure 2.4F-H and 
(Airik et al. 2006)). 
 Native Tbx18 is expressed very early in development within the urogenital ridge 
(Bohnenpoll et al. 2013; Kraus et al. 2001). In ECR1-2870, we observed ß-gal staining beginning 
at E10.5 in the urogenital ridge, in a manner very similar to native Tbx18 expression (Figure 
2.5A). At E11.5 staining had expanded in the region of the urogenital sinus (Figure 2.5B). By 
E14.5, staining had localized to the perimeter of the ureter in the region of the forming smooth 
muscle layer (Figure 2.5C). Staining persists in the ureter through E15.5 but is then reduced to 
small clusters of cells coating the ureter perimeter (Figure 2.5F-J). Using a smooth muscle actin 
(SMA) antibody, we stained late gestation ureter sections that had previously been stained by ß-
gal. Most of the ß-gal stained cells were in the periureteric mesenchyme, but many co-stained 
with SMA within the smooth muscle layer (Figure 2.5I,J).  
By E13.5 we also detected ECR1-driven LacZ activity in several other tissues known to 
express Tbx18. For example, strong staining was detected in the interdigital mesenchyme and 
portions of the limb (Figure 2.5E). Expression was also detected in the vibrissae (Figure 2.5D), 
and the testes (Figure 2.5C), which are known sites of late Tbx18 expression (Bohnenpoll et al. 
2013; Kraus et al. 2001; Wang et al. 2009). We also observed staining in the bladder, which has 
been recently reported as containing Tbx18-positive derived cells (Bohnenpoll et al. 2013) and in 
developing ovaries (not shown). In contrast to ureter, clear phenotypes have not been reported in 
any of these tissues in Tbx18 null mutants (Bohnenpoll et al. 2013), and we did not identify any 
obvious abnormalities in 12Gso mice (not shown).  
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Discussion: 
Data presented here identify the 12Gso translocation as a regulatory mutation of Tbx18, 
affecting the developmental expression both spatially and temporally from a distance of 
approximately 78 kbp downstream of the T-box gene. As demonstrated by quantitative RT-PCR 
and IHC, 12Gso does not completely ablate Tbx18 expression but does alter levels of Tbx18 
mRNA and protein with differential tissue- and at least in ureter, developmental time-specific 
effects (Figure 2.4). Concordantly, phenotypes associated with 12Gso also vary in their severity 
relative to the Tbx18-null allele. For example, patent hydronephrosis is detected later in 12Gso 
mice than in Tbx18-/- animals, and 12Gso and compound-mutant animals can be long-lived 
(Figure 2.2). However, all 12Gso homozygotes eventually develop hydronephrosis, and all 
display severe skeletal malformations that are nearly indistinguishable from Tbx18-/- mice 
(Figure 2.1). These data pointed to the importance of one or more critical Tbx18 enhancers 
required for proper urogenital and somite expression and located downstream of the gene, near 
or beyond the 12Gso breakpoint site. 
  A recent study using a Tbx18 BAC reporter provided strong evidence that most of the 
enhancers required to drive Tbx18’s pattern of developmental expression should be contained 
within a 209 kbp region extending upstream and downstream of the gene (Wang et al. 2009). 
Indeed, expression in urogenital tissues, heart, limbs, vibrissae, and other tissues were largely 
recapitulated by the BAC reporter. The one exception to faithful expression was noted in 
somites: BAC reporter activity was mostly limited to tail somites and was not seen in the regions 
anterior to the tail (Wang et al. 2009) whereas native Tbx18 expression is also expressed strongly 
in the anterior somites (Kraus et al. 2001; Bussen et al. 2004). These data suggested that whereas 
somite enhancers might lie outside the region spanned by the BAC, an enhancer critical to ureter 
expression should be located in the narrow interval defined by the proximal 12Gso breakpoint 
and by the end of the region spanned by RP23-353o7 on the distal side.  
This ~4 kbp region, which we call ECR1, includes patches of DNA sequence that are 
highly conserved in mammals; 12Gso disrupts one of these conserved patches including binding 
sites for TF proteins with known roles in urogenital and smooth muscle development, including 
GATA proteins, GATA2, 3, 4, and 6 and LBP1 (also called TFCP2) (Figure 2.3) (Kang et al. 
2004; Trowe et al. 2012; Zhou et al. 1998; Wada et al. 2000). Using a transgenic reporter, we 
have confirmed the presence of at least one enhancer in the ECR1 region directing reporter gene 
	   
 
 
28 
expression in urogenital tissues. ECR1 also drives reporter expression in a portion of the limbs, 
the vitelline veins, and vibrissae in a manner that matches previously published Tbx18 expression 
domains (Figure 2.5) (Kraus et al. 2001; van Wijk et al. 2009).  
The expression pattern driven by ECR1 also differs in subtle ways from native Tbx18 
expression; we posit that these discrepancies are due to the isolation of ECR1 from its natural 
genomic context in the transgenic mice, and the importance of interactions between ECR1 and 
other regulatory elements in the intact context of this extended locus. Indeed, it is likely that 
ECR1 includes just a subset of the active enhancers controlling Tbx18 expression in the 
urogenital tract and in other tissues throughout development. Interactions between these elements 
are likely to confer nuanced specificity to Tbx18 expression that cannot be recapitulated with an 
isolated element in transgenic mice. For example, both ECR1 and BAC RP23-353o7 drive 
continued expression of the reporter gene throughout gestation, and thus beyond the time when 
native Tbx18 mRNA and protein is detected (Figure 2.4B-G and (Airik et al. 2006). One 
explanation could be that regulatory elements contained in both ECR1 and RP23-353o7 are 
required to activate or maintain Tbx18 in the ureter mesenchyme, but are eventually repressed by 
elements located outside the RP23-353o7 region.  
However, the notion that ECR1 might function to maintain Tbx18 expression during later 
prenatal stages is especially intriguing, given the expression pattern we observed during ureter 
development in 12Gso/Tbx18- compound mutant mice. Specifically, our data suggest that 
TBX18 protein is expressed normally until approximately E12.5, but disappears from developing 
ureter tissues in mutants around E13.5 (Figure 2.4). Although we cannot rule out a role for more 
distant enhancers or silencing elements, we hypothesize that ECR1 is required in cis for full 
expression and function of Tbx18 during ureter development.  Specifically we propose that 
ECR1 functions to maintain Tbx18 expression beyond E12.5 in this tissue, and that the 
separation of this element from the Tbx18 gene underlies the premature loss of Tbx18 expression 
in 12Gso mutant ureters.    
How ECR1 might function in this capacity remains uncertain.  However, recent work has 
shown that Tbx18 expression is maintained after E12.5 in the ureteric mesenchyme through the 
action of epithelial Wnt7b and Wnt9b (Bohnenpoll et al. 2013; Trowe et al. 2012). These reports 
raise the intriguing possibility that WNT signaling might be mediated directly through 
interactions with ECR1.  Supporting this notion, the WNT-activated transcription factor, LEF1, 
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is one of the TFs with a conserved motif in ECR1; furthermore, this motif is positioned just distal 
of the 12Gso breakpoint site (Figure 2.3C). It is thus enticing to speculate that 12Gso directly 
disrupts essential and conserved WNT-mediated signaling events by severing the connection 
between ECR1 and the Tbx18 gene.  This hypothesis can be tested directly by chromatin 
immunoprecipitation and other experiments in future studies. 
 The expression pattern we documented and the hypothesis that ECR1 is required to 
maintain, but not to initiate Tbx18 expression during development may also help explain the 
milder ureter phenotype observed in 12Gso compared to Tbx18-/- mice. For example, unlike 
Tbx18-/- mice, 12Gso/12Gso newborns exhibit only mild hydronephrosis although with patent 
hydroureter (Figure 2.1). The hydronephrosis phenotype is more distinct in the compound mutant 
than in 12Gso homozygotes, but still not as severe as that seen in Tbx18-/- embryos. The 
expression of Tbx18 in the correct cells initially, but restriction to a subset of cells in the ureteric 
mesenchyme by E13.5 in 12Gso mutants, suggests a cell-type specific effect that could explain 
the milder 12Gso phenotype (Figure 2.4). Specifically, the 12Gso mutation attenuates or 
abrogates expression of Tbx18 in the mesenchymal cells proximal to the ureter epithelium but 
not distally, in a time-dependent manner. Expression in these cells is clearly not sufficient to 
direct normal smooth muscle development, since adult 12Gso/12Gso and 12Gso/Tbx18- 
compound mutant animals show disorganized smooth muscle and urothelium in the ureter 
proximal to the kidney (Figure 2.2). Interestingly, the small amount of TBX18 that does exist in 
mutants appears to be capable of activating Sox9 downstream in the mesenchyme and epithelium 
(Figure 2.4B-G’). We found SOX9 protein to be abundant in both cell layers of 12Gso/Tbx18- 
compound mutant ureters at E15.5; this is not the case in Tbx18-/- animals, where Sox9 is absent 
(Airik et al. 2010). As previously remarked, the expression patterns of Tbx18 and Sox9 in the 
developing ureter are similar in location and timing, and both are essential to proper patterning. 
Data presented here suggest that the temporary activation of TBX18 expression around E12.5 
may be sufficient to permit continued expression of SOX9 in the E15.5 12Gso/Tbx18- mutant 
ureter, likely contributing to the lesser severity of the ureter phenotype in 12Gso mice. 
 ECR1 therefore likely plays an important role in the 12Gso ureter phenotype, but since 
ECR1 is not expressed in somites, the disruption of this element cannot explain the skeletal 
abnormalities that are very clearly displayed by 12Gso mutants and 12Gso/Tbx18- compound 
mutant mice. This fact, and previous reports that the BAC RP11-353o7 reporter transgene also 
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does not completely recapitulate Tbx18 somite expression (Wang et al. 2009), leads us to surmise 
that enhancer(s) critical to anterior somite expression will be found beyond the boundaries of the 
BAC reporter and of ECR1, and thus further downstream of the Tbx18 gene.  
Additional Tbx18 enhancer elements may also be found in this distal downstream region. 
For example, qRT-PCR experiments indicate reduced quantities of Tbx18 in the whole torso by 
E12.5, although IHC shows that TBX18 protein is present at significant levels in the ureteric 
mesenchyme at this point (Figure 2.4). Thus, Tbx18 transcripts may be depleted in other tissues 
in the lower torso. This difference, and others, could possibly contribute to the relative longevity 
of 12Gso compared to Tbx18-null animals. In other words, the translocation may allow Tbx18 to 
be expressed in certain cell types that are essential to postnatal survival. Specifically, while 
virtually all Tbx18-null mutants die perinatally (Bussen et al. 2004), 12Gso homozygotes and 
12Gso/Tbx18- animals survive at least to neonatal stages and some live well into adulthood. As 
we have noted, the ureter phenotype of 12Gso mutants appears later, and is less severe than that 
seen Tbx18-/- mice, and this difference could possibly enable postnatal survival. However, it is 
likely that expression in other cell types plays an as yet undiscovered role. Further studies will be 
required to unravel the specific causes of Tbx18-linked perinatal lethality and the biological 
differences that explain the relative health and longevity of 12Gso mutant mice. 
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Materials and methods: 
Breakpoint mapping. 
Based on previously published data (Chittenden 2002) we designed primers within exons 
34 and 35 of the Abca1 gene for genome walking (Genome Walker Kit, Clontech Laboratories, 
Mountain View CA USA; primers abca1-34 GCAGGGCTGGATACGAAAAACAATGTCAAG 
and abca1-35 ATAGCATGCCAGCCCTTGTTATTGAACCAC). DNA fragments retrieved 
from these experiments were sequenced and chr9 junction sequences were identified by BLAST. 
We designed primers from the chr9 flanking region (CTGAAGGTGCTTTCTGCCTC) and used 
this primer with the abca1-34 primer to genotype mutant animals and embryos. 
 
Histology and immunohistochemistry. 
 The TBX18-2 polyclonal antibody was generated under contract with Abgent, Inc (San 
Diego, CA) by attaching the peptide sequence (qqqlqkkrrklateea) to KLH and immunizing 
rabbits. Adult tissues were preserved in 4% paraformaldehyde in PBS. Post-fixed tissues were 
dehydrated, embedded in paraffin and sectioned for staining. Thin-sectioned tissues were stained 
with Hematoxylin and Eosin as previously described. Embryos were fixed in 4% PFA overnight 
at 4ºC. They were then dehydrated and embedded in paraffin for sectioning. Four micron 
sections were deparaffinized, boiled for 30 minutes in citrate target retrieval solution pH 6.0, 
then treated with 3% H2O2 for thirty minutes. Slides were blocked with goat blocking serum for 
1 hour, and then the TBX18-2 (1:800), Sox9 (1:400)(Abcam ab3697) and alpha-Smooth Muscle 
Actin (1:1000)(Abcam ab5694) antibodies were incubated overnight at 4ºC. Sections were 
washed and a goat-anti-rabbit-HRP (Jackson Immunoresearch) secondary antibody was applied 
at 1:400 for one hour at room temperature. Sections were then stained with Perkin-Elmer TSA-
Rhodamine for three minutes, washed and counterstained with Hoechst 33342.  
 
Blue/red skeletal preparations. 
  Animals were sacrificed with CO2 to prevent damage to the skeletal structure. Dead 
animals were skinned and eviscerated. The bodies were stored in 95% ethanol overnight with 
rocking for fixing. Post-fixed carcasses were stored in 100% acetone for 24 hours to dissolve 
adipose stores. For 1-5 days, the body was washed in 1% KOH with frequent changes, until most 
of the skeletal muscle was transparent. The solution was changed to blue stain (0.05% alcian 
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blue, 80% ethanol, 20% glacial acetic acid) for 24-48 hours depending on the age of the mouse. 
The skeletons were then cleared in 1% KOH overnight. Then the solution was changed to red 
stain (0.03% alizarin red, 1%KOH) for 30 minutes. After red staining, they were washed in water 
and cleared in 1% KOH. 
  
ECR1 construct and transgenic mice. 
  The ECR1 transgenic construct was created using the Hsp68-LacZ vector (a generous gift 
from Len Pennacchio). The ECR was amplified out of BAC RP23-461h11 with Invitrogen Pfx 
high fidelity polymerase, and the isolated 4.5 kbp PCR product was cloned into pGemT-EZ. The 
insert was cut out of pGemT-EZ with SmaI and XhoI, and ligated into (ECR1)-Hsp68-LacZ. 
Digested product was injected into C57BL/6 X C3HF-F1 embryos and implanted in Swiss-
Webster surrogates. Transgenic mice were genotyped by PCR for the LacZ gene. ß-Gal staining 
was performed essentially as outlined in (Loughna and Henderson 2007). Incubations were 
performed at room temperature on a rocking plate. Embryos were tested for the presence of the 
transgenic construct by PCR for the LacZ transgene with primers TTTCCATGTTGCCACTCGC 
and AACGGCTTGCCGTTCAGCA to produce a 350bp product. 
  
Tbx18 qRT-PCR. 
  RNA was collected by homogenizing embryos in Invitrogen Trizol reagent. RNA was 
DNase treated with Qiagen on-column protocol on RNeasy columns. Invitrogen Superscript III 
reverse transcriptase was used to generate cDNA. Tbx18 mRNA levels were detected by qRT-
PCR with Qiagen Tbx18 QPCR primers Cat#QT00133140. Mouse Gapdh QPCR primers 
(QT01658692) were used for normalization. An Applied Biosciences 7900HT thermocycler was 
used for amplification. The delta-delta-Ct method was employed to establish quantity 
differences. Embryos were dissected into four parts, full limbs were separated from the torso, 
heads were removed at the base of the neck, and torsos were bisected above the liver to produce 
upper and lower torso halves. 
 
Animal Breeding and Welfare. 
 Because 12Gso is a reciprocal translocation, the carrier animals are naturally semi-sterile; 
breeding rates are particularly low when these mutations are maintained on an inbred 
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background (Elso et al. 2008). For that reason, we maintained 12Gso animals, and all of the other 
genotypes used in this study, on an F1 hybrid background (C3H/HeJ x C57BL/6J). Specifically, 
we maintained the mutant line by breeding heterozygotes to B6C3-F1 animals at each 
generation.  
Animal work described in this study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Institutional Animal Care and Use 
Committee of the University of Illinois (Animal Assurance Number: A3118-01; approved 
IACUC protocol number 11030) 
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Figures and Tables. 
Figure 2.1 
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Figure 2.1 (cont.). The 12Gso chromosome translocation is an allele of Tbx18 and produces 
recessive phenotypes that are similar to the Tbx18-null mice. (A-E) H&E stained sections of 
newborn thoracic vertebrae. Fused and malformed vertebrae are indicated with black arrow. (F-J) 
Alizarin red and alcian blue stained axial skeletons from newborn mice. Expanded proximal ribs 
are indicated with red arrows. (K-O) Lateral views of newborn thoracic skeletons. Fused pedicles 
of adjacent vertebrae are indicated with red arrows. (P-T) Hematoxylin and Eosin stained 
sections of newborn kidneys and ureters. 12Gso/12Gso and 12Gso/Tbx18- newborns display 
patent hydroureter (black arrows). (U-Y) Newborn urogenital systems in whole mount. The 
dilated ureters are outlined in black for clarity.  
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Figure 2.2
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Figure 2.2 (cont.). 12Gso mutants can survive into adulthood. (A) Three week old 12Gso/Tbx18- 
female (left), and wild type female littermate (right) demonstrating the shortened body length of 
the mutants. (B-B’) Thoracic skeletons of adult 12Gso/Tbx18- animal and (C-C’) wild type 
littermate. Red arrows indicate bifid ribs. (D-F) H&E stained kidneys from wild type, 
12Gso/12Gso, and 12Gso/Tbx18- respectively. (D’-F’) Anti-SMA (red) stained proximal ureters. 
“E” and “S” with arrows indicate urinary epithelium and smooth muscle, respectively. (D’’-F’’) 
H&E stained proximal ureters. 
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Figure 2.3 
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Figure 2.3 (cont.). The 12Gso breakpoint. (A) Sequence of the 12Gso breakpoints on Mmu4;9 
and Mmu9;4. Bold text indicates sequence homology between the two chromosomes. (B) Map of 
the Mmu9 Tbx18 locus (not drawn to scale). The 12Gso breakpoint is located 78 kbp 
downstream of the 3’ end of Tbx18. The enhancer ECR1 spans the 12Gso breakpoint and 
contains a highly conserved cluster of elements. The BAC RP23-353o7, which spans 210 kbp of 
the Tbx18 locus was reported to contain a somite and ureter enhancer, and extends just past the 
12Gso Mmu9 breakpoint. (C) A map of mammalian conservation and conserved transcription 
factor binding motifs surrounding the 12Gso breakpoint within ECR1. At the bottom of the 
figure is a percent identity plot (PIP) from the ECR browser {Ovcharenko:2004hy} showing 
sequence similarity across a ~1 kbp region surrounding the 12Gso breakpoint within the ECR1 
sequence. Percent identity (between 50-100% in 100 bp windows) is traced over the region to 
identify regions with significant sequence homology between the mouse sequence and regions in 
the human (hg19), bovine (bosTau6), and opossum (monDom5) genomes. The conserved regions 
are filled with red by default in the ECR browser if they include sequence identity above 70% in 
100 bp windows. Above the PIP plot is a map of the locations of transcription factor binding 
motifs, identities of which are listed at left, that are conserved in all four species. The 
approximate location of the 12Gso breakpoint is shown as a black dashed line. 
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Figure 2.4 
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Figure 2.4 (cont.). Expression patterns of Tbx18 in 12Gso mutant mouse embryos. (A) 
Quantitative reverse transcription PCR in whole E10.5, E11.5 and E12.5 heads, limbs, upper 
torsos, and lower torsos. Tbx18 mRNA levels are significantly reduced in E10.5, E11.5, and 
E12.5 heads, and torsos, but not in E12.5 limbs. Asterisks indicate tissues where Tbx18 is 
significantly reduced in compound heterozygotes compared to wild type. For all genotypes, 
stages, and tissues, n ≥ 4, error bars are Standard Error of the Mean. (B-G) IHCs on wild type 
and 12Gso/Tbx18- embryos at E12.5, E13.5, and E15.5. (B’-G’) SOX9 IHCs on adjacent 
sections. (B-C) At E12.5 TBX18 is detected strongly in the forming ureter mesenchyme in both 
genotypes. TBX18 is not detected in the ureter epithelium. White dashed lines encircle the ureter 
epithelium in all panels for clarity. (D-E) By E13.5, the protein is still detected but only in cells 
located distally from the ureter epithelium of mutants (arrows in E) while being strongly 
expressed in condensed mesenchyme adjacent to the epithelium in wild type animals. At this 
stage, SOX9 is present in mesenchyme (“M” with arrow) and epithelium (“E” with arrow). (F-G) 
TBX18 is not detected in ureter mesenchyme by E15.5 in mutants and wild types but SOX9 
expression is still present in both genotypes (F’-G’).  
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Figure 2.5 
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Figure 2.5 (cont.). The ECR1 enhancer which spans the 12Gso breakpoint contains a urogenital-
active enhancer element. (A) At embryonic day E10.5, the enhancer directs LacZ expression in 
the urogenital ridge (black arrow) and the vitelline vein (white arrow). (B) Expression at E11.5 is 
primarily localized to the urogenital mesenchyme (black arrow). (C) E14.5 dissected urogenital 
system shows strong staining in the ureter mesenchyme “U” and testes “T”. (D-E) LacZ is also 
expressed in the developing whisker buds, maxilla and mandible, eyecup, forebrain, and limbs as 
previously reported for the Tbx18 mRNA {Kraus:2001tx, Airik:2006kv}. (F-H) Sections of LacZ 
stained E16.5 ureters and bladder showing expression in the ureter mesenchyme. (F) Black 
arrows indicating β-galactosidase stained cells along the length of the ureter. (G) Bladder 
indicated “B” and urethra is indicated by “R”. Blue staining is observed in a portion of the 
bladder stroma. (I) The urinary epithelium is labeled “E” and the differentiated smooth muscle 
layer is labeled “S”. The black dotted lines indicate the apical surface the urinary epithelium. (I-
J) E16.5 ureters co-stained with LacZ (blue) and anti-SMA (red). (J) In the ureter section closest 
to the bladder, LacZ positive cells are dispersed through the mesenchyme.  
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Chapter 3 
Tbx18 maintains proliferation of urogenital sinus mesenchyme essential to the 
formation of the ventral prostate lobe. 
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Abstract: 
 The T-box transcription factor gene Tbx18 is essential to the differentiation of the smooth 
muscle stroma in the upper urinary system, with Tbx18 null (Tbx18-/-) mutants displaying 
ureteric malformation and severe hydronephrosis. Very similar differentiation processes 
characterize stromal development in other tissues including the prostate, suggesting that Tbx18 
could play a wider biological role. Here we demonstrate a clear failure of ventral prostate 
development in Tbx18 mutant mice. Prostate abnormalities are subtly apparent at birth, when 
most Tbx18-/- mice die. To examine prostate development post-natally, we used a relatively long-
lived Tbx18 mutant, called 12Gso. As in the ureter, mesenchymal cells in the urogenital sinus fail 
to condense into smooth muscle stroma in the mutant mice. Furthermore, by five weeks of age, 
the mutant prostate epithelium becomes severely hyperplastic and grossly disorganized. To 
identify molecular events that precede the onset of this pathology, we compared gene expression 
in the urogenital sinus of Tbx18-/- and wild type littermates at two embryonic stages. Genes that 
regulate cell proliferation, smooth muscle differentiation, and development of the prostate 
epithelium were significantly affected in the mutant urogenital sinus at early stages, suggesting a 
direct role for Tbx18 in regulating those genes. Using the 12Gso mutant, we confirmed that a 
distally located urogenital enhancer is likely required for Tbx18 ventral prostate expression. 
Together, these results argue that Tbx18 is essential to the differentiation and maintenance of the 
prostate smooth muscle stroma, and indirectly regulates epithelial differentiation through control 
of stromal-epithelial signaling. 
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Introduction: 
The T-box transcription factor TBX18 performs a vital role in the formation of multiple 
organs during gestation. The absence of Tbx18 gene expression at the appropriate formative 
stages produces organ defects ranging from under-sized, poorly functioning structures to 
complete loss of function (Bussen et al. 2004; Airik et al. 2006; Trowe et al. 2008; Wu et al. 
2013). The urogenital system is one system that is most severely affected in Tbx18 null mutant 
(Tbx18-/) mice; in particular, Tbx18-/- animals exhibit hydroureter and hydronephrosis at birth. In 
wild type mice, Tbx18-expressing mesenchymal cells begin to coalesce on the nascent ureter 
epithelial duct beginning around embryonic day 12 (E12.0)(Airik et al. 2006). Secreted signals 
from the ureter epithelium maintain the proliferation and eventual differentiation of the 
condensing mesenchyme (Trowe et al. 2012; Wang et al. 2009a; Yan et al. 2014). By contrast, in 
the absence of Tbx18, most of these coalescing mesenchymal cells fail to respond to the 
epithelial signal and subsequently undergo apoptosis or retire to a fibrocytic fate some distance 
from their normal destination. Consequently, an unknown signal that resides downstream of 
Tbx18 in the differentiating ureteric mesenchyme is prevented from inducing the corresponding 
proliferation of ureter epithelium. Due to the loss of these interconnected proliferation and 
signaling mechanisms in Tbx18-/- animals, neither the ureter epithelium nor the stroma proliferate 
sufficiently. Tbx18 mutant mice thus develop a ureter of reduced length, thickness, and elasticity 
and the consequent fluid build-up leads to a grotesque enlargement of both ureter and kidneys 
(Airik et al. 2006; Bolt et al. 2014). 
 Toward the posterior end of the urogenital system, the prostate is an organ essential to 
male fertility providing a nutritionally rich medium for sperm at the moment of ejaculation. Male 
mice that lack a functional prostate exhibit significantly reduced fertility (Pang et al. 1979). The 
formation of the prostatic semen appears to require the profligate turn-over of prostate epithelial 
cells throughout adulthood. However, one negative consequence of this constant proliferation is 
that the prostate is also the most common source of cancer in males from Western cultures 
(Siegel et al. 2013). More frequently than cancer, benign prostate hyperplasia is so prevalent that 
some studies indicate it may affect as many as 60% of men over age 60 with a proportional 
increase every year after (Lepor 2004). Perhaps then it is unsurprising a number of 
transcriptional regulators have been defined with well-described functions in the formation and 
maintenance of prostate epithelium (Thomsen et al. 2008; Kurita 2004; Nelson et al. 2002; 
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Bhatia-Gaur et al. 1999; Mehta et al. 2013; Wu et al. 2011). This is in stark contrast to the 
prostate stroma where there is a conspicuous dearth of knowledge regarding the top-level 
transcriptional regulators that control the formation of this organ from its developmental anlage, 
the urogenital sinus (Welsh et al. 2011; Smith et al. 2002; Podlasek et al. 1997). 
The prostate arises developmentally from the urogenital sinus (UGS), a small 
enlargement of the urethra located at the base of the bladder. Beginning around embryonic day 
16.5 (E16.5), the urogenital sinus mesenchyme (UGS-M) begins differentiation and 
simultaneously induces the adjacent urethral epithelium (UGS-E) towards a path of prostate 
committal, in a process that is highly reminiscent of ureter development (Donjacour and Cunha 
1995; Cai et al. 2013). The UGS-E, responding to multiple paracrine signaling mechanisms, 
begins to invade the adjacent undifferentiated mesenchyme (Sugimura et al. 1986; Zhu et al. 
2007; Zhang et al. 2008; Grishina et al. 2005; Lai et al. 2012). As the epithelial buds extend into 
and beyond the UGS-M, the UGS-M condenses around the buds producing the early rudiments 
of the prostate stromal layer, comprised mostly of differentiating smooth muscle cells and 
fibroblasts. Any perturbation of the reciprocal epithelial-mesenchymal signaling results in 
abnormal prostate development (Mehta et al. 2013; 2011; Wu et al. 2011; Yu et al. 2010; Vezina 
et al. 2008). 
Due to the powerful influence of signaling pathways much work has focused on the 
actions of paracrine factors such as Wnts (Mehta et al. 2011), Bmps (Grishina et al. 2005), and 
Shh (Podlasek et al. 1999). Some of these signals direct lobe-specific patterning of prostate 
development. Others, such as Notch, appear to control proliferation in a general manner. When 
Notch is activated in the UGS-E and adjacent UGS-M, it functions to control the proliferation of 
both the prostatic epithelium and stromal smooth muscle (Wu et al. 2011). The combined 
regional specificity of these signals is likely to control how each prostate lobe acquires its form 
and function. How the temporal and spatial expression of these factors is controlled and 
knowledge of the transcription factors that regulate them is a lingering gap. 
 A number of studies have indicated that the transcription factor TBX18 contributes to 
structures in the urogenital system aside from the ureter, suggesting the possibility of 
undiscovered postnatal phenotypes (Bohnenpoll et al. 2013; Wang et al. 2009b; Xu et al. 2014; 
Blum et al. 2010). However, since Tbx18-null animals die perinatally (Bussen et al. 2004), post-
natal phenotypes have been difficult or impossible to discern. We recently reported a novel, 
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hypomorphic regulatory mutation of Tbx18, called 12Gso, which expresses a clear hydroureter 
phenotype but is relatively long-lived. The 12Gso mutation separates Tbx18 from distal 
downstream enhancers, including one enhancer element, called ECR1, with an essential role in 
urogenital development (Bolt et al. 2014). The relative longevity of 12Gso mice offers the 
opportunity to examine postnatal phenotypes associated with reduction of Tbx18 expression 
levels in urogenital tissues.  
Here we report a novel phenotype of the prostate associated with both the Tbx18-/- and 
12Gso mutations. We show that Tbx18 regulates the formation of the prostate stroma 
contributing specifically to the ventral and dorsal prostate lobes. In contrast to the ureter, which 
displays reduced stromal thickness in mutant animals, Tbx18 mutant adult prostates have 
hypertrophied stromal layers and somewhat surprisingly, given the fact that Tbx18 expression is 
limited to the stroma, significantly hyperplastic and disorganized epithelia. This suggests an 
important role for Tbx18 in mediating and regulating the appropriate prostate epithelial-stromal 
signaling and proliferation of both components, with implications in human prostate disease. 
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Results: 
Tbx18 is expressed in the early urogenital mesenchyme. 
 Previous reports of the Tbx18 expression pattern have not included analysis of the 
urogenital sinus or prostate. However, the obvious parallels between ureter and prostate 
development prompted a second look. We first set out to determine the quantity and location of 
Tbx18 expression through the late stages of gestation and the post-natal days through puberty. 
Using reverse transcript PCR (RT-qPCR) we detected Tbx18 mRNA at increasing levels in the 
urogenital sinus through gestation and the first few days after birth. Beginning after postnatal day 
three (P3), Tbx18 mRNA levels dropped towards the detection limits of the qPCR thermocycler 
over the first two weeks post-natal (Figure 3.1A).  
 We then used immunohistochemistry (IHC) with a tested TBX18 antibody (Bolt et al. 
2014) to confirm TBX18 protein levels and to provide spatial resolution regarding the location 
and timing of TBX18 from E16.5 to P3. We observed changes in TBX18 protein levels by IHC 
that were consistent with patterns determined by RT-qPCR (Figure 3.1B). At E16.5, TBX18 
staining is observed on the dorsal and ventral aspects of the UGS-E, directly adjacent to the 
epithelium. At P0, TBX18 continues to be detected next to the UGS-E with strong staining 
around epithelial prostate buds. By P3, TBX18 was detected in small clusters of cells in the 
UGS-M around prostate buds. We also wanted to determine the relationship between TBX18 
expression and smooth muscle formation during these stages. To do so we complemented this 
study with an analysis of alpha-smooth muscle actin (SMA) protein staining on adjacent 
sections. We observed SMA staining in cells that were frequently adjacent to TBX18 cells, but 
were largely in non-overlapping domains (Figure 3.1B). 
In addition, we wished to determine the fate of cells expressing Tbx18 during the 
gestational stages. To do so we used a lineage tracing system to track cells that had previously 
expressed Tbx18. Specifically, we crossed mice carrying a Cre knock-in to the Tbx18 locus (a 
generous gift from Sylvia Evans) with the Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J reporter line 
that expresses Tomato fluorescent protein in all cells, but in cells that express Cre-recombinase, 
the construct is recombined to express eGFP (Muzumdar et al. 2007). In this study, we observed 
that the fluorescent reporter allele is recombined indicating the presence of Cre-recombinase, as 
early as E16 in the UGS-M. We observed most GFP expression in the ventral mesenchyme, and 
in portions of the UGS-M directly adjacent to the UGS-E in the region of the prospective dorsal 
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and anterior lobes. In subsequent stages, GFP expression is limited to the nascent lobes in these 
regions. Interestingly we observed GFP expression almost exclusively in the stromal layer of the 
ventral and dorsal lobes in adults (Figure 3.1C). 
 
Reduced Tbx18 expression disturbs the formation of the UGS-E and UGS-M. 
 Recent reports of Tbx18 expression in the urogenital system indicate that this gene is 
expressed and contributes cells to multiple components including the kidney parenchyma, ureter, 
adrenals, gonads, and bladder (Bohnenpoll et al. 2013; Wang et al. 2009b; Bolt et al. 2014; Xu et 
al. 2014). These reports suggested that Tbx18 is also expressed in the lower urogenital tract. 
However, prostate development begins during late gestation, which was not evaluated in those 
studies.  
 Re-examining isolated tissues, we noted that the urogenital enhancer discovered in 
analysis of the 12Gso mutant is essential to maintaining Tbx18 expression in developing ureter 
(Bolt et al. 2014), also clearly drives strong expression of a LacZ (B-GAL) reporter gene in the 
developing UGS (Figure 3.1D). Since ECR1 is separated from the Tbx18 gene by the 12Gso 
mutation, these data suggested that we would identify Tbx18 gene expression differences, and 
potentially prostate phenotypes, in 12Gso mutants as well as Tbx18-/- mice.  
We first evaluated the affects of Tbx18 abrogation on E16.5 and P0 UGS in wild type 
mice, Tbx18-/- and hypomorphic 12Gso/Tbx18- compound heterozygotes, and observed two main 
changes in UGS structure. These changes were more dramatic in Tbx18-null animals compared 
to 12Gso/Tbx18- mutants, but were present in both genotypes. First we noticed that the UGS-E 
cells displayed increased cell volume as well as enlarged nuclei in mutants. The apical surface of 
the UGS-E of mutants had increased convolutions and irregularities (Figure 3.2). These 
differences are especially obvious on the dorsal and ventral aspects of the UGS-E (Figure 3.2). 
We also noticed a small but recognizable homogeneity to the structure of the mutant UGS-M. 
Specifically, we observed a characteristic pattern of higher UGS-M cell density around the 
forming prostate buds of wild type mice. This cell density pattern was absent in Tbx18-/- mutant 
animals and reduced in 12Gso/Tbx18- compared to wild type litter mates (Figure 3.2).  
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Expression analysis of Tbx18-null mutant UGS. 
 The P0 UGS phenotype (Figure 3.2) indicated that the earliest detectable role for Tbx18 
in prostate formation would be discovered between E16.5 and E18.5. This time period is also 
critical for the formation of the first prostate buds and marks the beginning of smooth muscle 
formation (Sugimura et al. 1986). For each E16.5 and E18.5 stage, we therefore isolated whole 
UGS from wild type and Tbx18GFP/GFP litter mates and performed RNA-Seq, comparing gene 
expression in mRNA from pooled tissues from each genotype at each stage.  
 Gene expression analysis identified 324 differentially expressed genes at E16.5 and 6101 
DEGs at E18.5 with an absolute log2 fold change greater than 1.0 (Supplemental 3.1). To 
determine which major categories of genes are differentially expressed in the absence of Tbx18 
at these two stages, we performed GO analysis on the sets of differentially expressed genes using 
the DAVID functional analysis program (Table 3.1)(Huang et al. 2008).  
 At E16.5 nearly every enriched Functional Category was related to myogenesis. These 
categories were especially enriched in genes that encode structural components of myofibrils 
including  Acta1, Actn2, Ttn, Tnnt2, Tcap, Jph2, Mypn, and Obscn among others (p-value 4.2E-
26).  In addition, several important muscle differentiation factors were down-regulated including 
Myf5, Myf6, Myod1, and Myog which act cooperatively to drive muscle proliferation and 
differentiation (Bentzinger 2012). In addition, Tbx4 (-1.06), Tbx5 (-1.25), and Tbx15 (-1.37) 
were down-regulated. At E16.5 several proteinase inhibitors were up-regulated especially within 
the Stephin family of Cathepsin inhibitors; Stfa1, Stfa2, Stfa2l1, Stfa3 (Table 3.1). 
 At E18.5, we identified significant enrichment for down-regulated factors involved in 
transcriptional control within the nucleus (enrichment score 4.5E-63) including the muscle 
differentiation factors Mef2A, Mef2C, and Mef2D. At this stage, we also observed significant 
differential expression of developmental genes including Sox9 (log2 fold change = -2.1), Shh (-
2.0FC), Hoxd13 (-2.5FC), Pten (-1.6FC) and Trp63 (-1.6FC), all genes with known roles in 
regulating formation of the urogenital sinus and prostate (Huang et al. 2012; Kurita 2004; Wu et 
al. 2011; Podlasek et al. 1997). We also observed at this stage a massive up-regulation of genes 
directly involved in the formation of the ribosomes (8.0E-12) and mitochondrial components 
(7.0E-12). 
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Changes in proliferation and apoptosis in the Tbx18-null urogenital sinus. 
 Overall, the Gene Ontology analysis of these DEGs indicated a significant enrichment for 
genes involved in cell growth and cell proliferation. These categories were particularly enriched 
at E18.5 (Table 3.1). Several of the differentially expressed genes are known to perform vital 
roles in the growth and proliferation of the urogenital sinus. Specifically, we observed down-
regulation of Sox9, Trp63, Pten, and Hoxd13, all of which have important roles in promoting 
cell-type specific proliferation of the prostate (Huang et al. 2012; Kurita 2004; Wu et al. 2011; 
Podlasek et al. 1997). In contrast, we observed an increase in mitochondrial and ribosomal genes, 
implicating cell growth. The gene expression changes we observed in whole Tbx18-/- UGS 
provide no spatial resolution to tell us which cells are proliferating and which are not. To 
determine which cells are affected by this predicted functional change, we tested for an increase 
in KI67 protein, which is a marker for cell proliferation (Scholzen and Gerdes 2000) in sectioned 
tissues. Additionally, Tbx18 loss-of-function is associated with programmed cell death in somites 
and ureter. While an apoptotic fate for Tbx18-null cells in the UGS-M conflicts with the enriched 
and up-regulated mitochondrial and ribosomal GO categories we predicted that these two 
processes might be spatially separated in the UGS. To resolve this conflict, we used the TUNEL 
assay to examine potential changes in apoptosis in the sectioned mutant tissues.  
 At E16.5 we observed no significant change in either proliferating cells (KI67) or in 
apoptosis (TUNEL) between wild type and mutant mice (Figure 3.3). However at P0 we 
observed a decrease in the KI67 proliferation marker in both the UGS-E and adjacent UGS-M in 
mutant mice. In the wild type UGS-E, the KI67 antibody stained ubiquitously and in the UGS-M, 
proliferating cells were located in the mesenchyme proximal to the dorsal and ventral aspects of 
the UGS-E (Figure 3.3). In contrast, in the Tbx18-/- and 12Gso/Tbx18- compound mutants, we 
observed significantly lower levels of KI67 staining at P0, with no obvious changes specific to 
one compartment (Figure 3.3). In both mutants at P0, we observed much stronger TUNEL 
staining in the UGS-M than we did in wild type animals. Consistent with the fact that 12Gso is a 
hypomorphic mutation (Bolt et al. 2014), 12Gso/Tbx18- UGS-M showed levels of TUNEL 
staining intermediate between those of the Tbx18-null mutants and the wild type mice (Figure 
3.3). The hypomorphic character of 12Gso is also consistent with the intermediate UGS 
phenotype in compound mutants at P0 (Figure 3.2). The observed increases in TUNEL staining 
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were located primarily on the dorsal and ventral aspects of the UGS-E in the UGS-M. We 
observed no change in TUNEL staining in the UGS-E (Figure 3.3). 
 
Loss of Tbx18 primarily affects the ventral prostate lobe. 
 At birth, we observed consistent distortions in the morphology of the urogenital sinus 
mesenchyme and epithelium of Tbx18 mutants (Figure 3.2). Because the bulk of prostate 
development occurs after birth, we focused on examining 12Gso/Tbx18- compound 
heterozygotes. In animals that survived to adult stages, we observed a massive enlargement of 
the ventral prostate stroma (Figure 3.4). Specifically, there was a marked increase in the 
thickness of the stromal smooth muscle layer, with muscle cells that have significantly increased 
overall size and reduced orientation within the muscle strands (Figure 3.4). To determine if these 
prostates have increased cell number or increased cell size we measured the thickness of the 
stroma around the ventral prostate as well as counted the number of nuclei. From these 
measurements we found that the mean stromal width was significantly larger in mutants on 
average: 45um+/-6.9um in wild type, 68.2+/-7.3um and 71.0+/-11.0um for the 12Gso/Tbx18- 
mutant prostates. By measuring the ratio of the number of nuclei per stromal width, we can 
establish a cell volume ratio; in 12Gso/Tbx18- mutants we observed a decrease in the number of 
nuclei per width supporting a hypertrophy model in the prostate stroma (Figure 3.4). This 
phenotype appears to be unique to the ventral prostate, as we did not observe similar changes in 
other lobes (Figure 3.4B). In the five week-old 12Gso/Tbx18- mutants we examined, the ventral 
prostate epithelial layer structure was partially preserved in portions of the gland. In other 
portions of the same lobe, we observed masses of epithelial cells with a complete loss of 
adherence to the epithelial membrane (Figure 3.4A-F). These cells did not display any consistent 
epithelial morphology, but rather appeared to be loosely associated.  
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Discussion: 
 This study provides the first evidence for a novel and essential role for the T-box 
transcription factor Tbx18 in development of the prostate. Tbx18 is expressed as early as E16.5 in 
the urogenital sinus mesenchyme (UGS-M), with expression peaking around post-natal day P3 
and declining thereafter. On the cellular level, expression is observed throughout the ventral 
mesenchyme and also dorsally, in mesenchymal cells positioned directly adjacent to the UGS-E. 
In wild type animals, these Tbx18-positive mesenchymal cells differentiate into the stromal 
smooth muscle cells of the prostate, largely contributing to the ventral prostate, but also in lesser 
degrees to the dorsal prostate lobe (Figure 3.1).  
Throughout development we observed TBX18 protein expression to have very little 
overlap with the smooth muscle actin marker (Figure 3.1B). This is consistent with the findings 
in ureter, which showed that Tbx18 expression is necessary for and predates smooth muscle 
differentiation, and that the eventual reduction of Tbx18 is required for the final transition to a 
smooth muscle phenotype (Airik et al. 2006; 2010; Nie et al. 2010). The pattern of TBX18 
preceding SMC formation in the urogenital sinus continues after birth (Figure 3.1B). 
 At the earliest recognizable stages of prostate development, around E16, we did not 
observe any differences in morphology in any of the mutant genotypes we examined. However, 
during the E18.5-P0 interval we observed a subtle but consistent difference in the structure and 
orientation of the UGS-M in Tbx18-/- and 12Gso/Tbx18- animals. This difference became more 
obvious around P0, at the time that the prostate buds begin growing rapidly (Figure 3.2). We also 
observed modest differences in the thickness and morphology of the UGS-E in mutants 
compared to wild type animals at P0. Specifically, we observed the UGS-E to have increased in 
thickness. In addition, epithelial cells at the dorsal and ventral aspects of the UGS-E displayed 
increased nuclear size (Figure 3.2).  
Although Tbx18-/- mice die at birth, we were able to determine the consequence of Tbx18 
insufficiency in post-natal prostate development using crosses between the hypomorphic 12Gso 
mutant (Bolt et al. 2014) and Tbx18-null mutant mice. In five week-old 12Gso/Tbx18- compound 
heterozygotes, we observed a dramatic phenotype specific to the ventral prostate lobe. The 
mutant prostates displayed a significantly hypertrophic smooth muscle layer, consisting of large 
SMA-expressing cells. In addition, we observed compaction of the ventral prostate epithelial 
folds with significant hyperplasia and apparent loss of cell identity in the mutants (Figure 3.4). 
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 To ascertain the molecular consequences of Tbx18 abrogation in the urogenital sinus we 
isolated whole UGS from Tbx18-null and wild type males at E16.5 and E18.5 for RNA-Seq 
analysis. This analysis revealed that smooth muscle differentiation is significantly perturbed, at 
least on the molecular level, as early as E16.5 by the loss of Tbx18 (Table 3.1). The large number 
of myofibril structural components that were differentially expressed points to the essential role 
of Tbx18 in activating expression of these genes. This also implies that smooth muscle 
differentiation is already underway at E16.5. At this stage, we also detected a significant up-
regulation of protease inhibitor genes. Specifically, the Stefin family of cysteine proteases 
inhibitors were up-regulated at E16.5. In sharp contrast, at E18.5 Stfa2, Stfa2l1, and Stfa3 were 
down-regulated. Also by E18.5 we detected a significant increase in expression of genes 
generally involved in cell growth including strong enrichment for ribosomal and mitochondrial 
genes (GO Biological Process p-values of 8.0E-12, and 7.0E-12 respectively).  
 One of the most highly enriched categories of down-regulated genes at E18.5 was 
transcriptional regulation (6.0E-46). Among these genes were several transcription factors with 
important roles in mediating cell-type specific differentiation. For example Hoxd13 (-2.5FC) 
loss-of-function results in reduced ventral and dorsal prostate size (Podlasek et al. 1997). Foxa1 
(-1.8FC) directly promotes cell growth in the prostate via an AR dependent pathway (Jin et al. 
2013). Sox9 (-2.1FC) is one of the earliest known markers of prostate development and loss of 
Sox9 before androgen receptor activation results in complete agenesis of the prostate (Huang et 
al. 2012). At later stages, Sox9 promotes basal epithelial proliferation and is regulated by Beta-
catenin (Wang et al. 2007; 2008). Notably, the B-catenin gene, Ctnnb1, was significantly down-
regulated in the E18.5 Tbx18 -/- UGS (Table 3.1); this gene is known to act downstream of Tbx18 
in the ureter, where it also promotes epithelial proliferation (Mehta et al. 2013; Airik et al. 2010). 
The Wilm’s tumor gene, Wt1, was also down-regulated at E18.5; Wt1 has been shown to interact 
with Tbx18 in other tissues such as in the heart where the two TFs act antagonistically to one 
another to control epithelial mesenchymal transition (Takeichi et al. 2013). Interestingly, many 
of these same developmental TFs are dys-regulated in prostate cancer (Wang et al. 2008; Huang 
et al. 2012; Jin et al. 2013; Schweizer et al. 2008), suggesting that the proliferative changes we 
have detected in Tbx18 mutant animals may presage prostate cancer-related cellular changes in 
older mice.  
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In addition to changes in the expression of these transcription factors, we also observed 
changes in a number of signaling molecules. This is especially true at E18, where several 
Fibroblast growth factors are down-regulated. Specifically, Fgf9 (-1.7FC) is expressed in the 
stroma and is a powerful inducer of stromal and epithelial prostate proliferation (Giri et al. 
1999). Fgf2 (1.0FC) is mitogenic towards the stroma where it is also expressed (Sherwood et al. 
1992). Fgf7 induces epithelial proliferation specifically and is associated with benign prostatic 
hyperplasia (-2.3FC)(Ropiquet et al. 1999). Finally, Fgf10 (-0.9FC) is a well characterized 
regulator of prostate bud formation and Fgf10-null animals present complete agenesis of the 
prostate buds at birth (Donjacour et al. 2003). At later stages, Fgf10 directs proliferation of the 
ventral prostate basal epithelial cells (Vezina et al. 2009). Furthermore, the cognate receptor of 
Fgf10, Fgfr2, mediates Fgf signaling to promote epithelial proliferation and induce prostate bud 
formation. This gene is down regulated also at E18.5 (-1.4)(Powers and Marker 2013).  
In addition to receiving Fgf signals, the Fgfr2 receptor is also linked to Notch signaling 
pathways in the prostate (Kwon et al. 2014). Notch signaling has been shown to regulate prostate 
stroma and epithelial development (Wu et al. 2011; Bertrand et al. 2014). At E16.5 we observed 
no changes in Notch signaling genes, but at E18.5 we found the Notch4 receptor to be up-
regulated (1.3FC). Additionally, we found Dll1 (0.8FC), Dll3 (1.2FC), and Dll4 (1.3FC) to be 
up-regulated in the Tbx18-/- UGS. Upon Notch activation by Dll1 and cleavage by gamma-
Secretase, the Notch Intracellular Domain binds Rbp-J (-1.2FC) to stimulate expression of the 
Hes/Hey transcriptional repressors in the prostate (Leong and Gao 2008; Bertrand et al. 2014). 
Over-expression or stimulation of these factors leads to prostate cancer (Bertrand et al. 2014). 
During normal prostate development, these factors cooperate to induce proliferation of the 
urogenital sinus and epithelium, but under abnormal conditions such as seen here, could possibly 
contribute to the differences we observe in Tbx18 mutant urogenital sinuses and prostates. 
With the methods used in this study, we cannot not link Tbx18 loss directly to dys-
regulation of these important prostate genes. However, their co-expression during prostate 
development, demonstrated here, and their dys-regulation in Tbx18 mutant mice supports the 
hypothesis that the functions of these TF genes are intimately linked. Our data show that Tbx18 
is critical to prostate development, and suggests that the T-box protein may interact with Sox9, 
Wt1, Foxa1, and Cttnb1 to maintain the tissue-specific proliferation of prostate epithelium and 
adjacent mesenchymal cells.  
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In contrast to the ureter, the cells that populate the adult ventral prostate epithelium 
appear to respond with vigor to the hypomorphic Tbx18 environment. The remaining smooth 
muscle cells increase significantly in mass, while the epithelial cells actively increase in number 
(Figure 3.4). This is quite different than in the ureter where the replacement stromal cells are few 
and undersized, and the epithelium is has reduced thickness and organization (Airik et al. 2006; 
Nie et al. 2010). From these data it remains unclear if the resulting adult epithelial phenotype is a 
direct correlate of Tbx18 loss of function, or is possibly a sequela of the abnormally 
differentiated stromal layer. Future studies will focus on pinpointing the mechanisms of Tbx18 
activities in developing prostate, and examine the long-term effects of Tbx18 insufficiency on 
adult prostate health. 
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Methods: 
Histopathology and Immunohistochemistry. 
Embryos were dissected at the appropriate gestational or post-natal stage. Embryos were 
placed on ice and fixed in 4% PFA at 4ºC, dehydrated, and embedded in paraffin wax for 
sectioning. 4um sections were used in all experiments. Tbx18-2 antibody is used at 1:800 in 
blocking solution and incubated overnight at 4ºC. Following washes, a goat-anti-rabbit:HRP 
(Jackson ImmunoResearch) secondary antibody was applied for 1hr at room temperature. 
Sections were covered in TSA-Rhodamine for 6 minutes then washed and counter stained with 
Hoecsht 33342. Commercial antibodies are CAS9 (Cell Signal 9664s 1:1000), TRP63 (Biorbyt 
orb99218 1:X00), KI67 (1:500), SOX9 (), GFP (1:500), and SMA (1:1000). TUNEL assay was 
performed as recommended using the TACS® TdT In Situ Apoptosis Detection Kit from R&D 
Systems.  
 
RT-qPCR. 
Total RNA was collected by homogenizing tissues in Invitrogen Trizol reagent. RNA 
was DNase I treated with NEB DNase I on Zymo Research RNA Clean & Concentrate 25 
columns. NEB M-MULV reverse transcriptase was used to generate cDNA. Tbx18 mRNA levels 
were detected by qRT-PCR with Tbx18 QPCR primers (sequences here). Mouse Gapdh QPCR 
primers (sequences here) were used for normalization. An Applied Biosciences QuantStudio Flex 
6 thermocycler was used for amplification. The delta-delta-Ct method was employed to establish 
quantity differences.  
 
RNA-Seq. 
Whole urogenital sinuses were dissected from male mouse embryos at embryonic day 
E16.5 and E18.5. Tissues were homogenized in Trizol and RNA was isolated. RNA was treated 
with NEB DNase I, then analyzed on a Bioanalyzer for quality. RNA-Seq libraries were prepared 
with KAPA Biosystems KAPA Stranded mRNA-Seq Kit for Illumina Platform (KR0960 - 
V2.14). Single-end reads were performed on Illumina Hi-Seq sequencers. Single stranded 
sequencing reads were processed with Tophat 2.1.0 (using Bowtie 2.1.o and Samtools 0.1.19) 
with all Tophat options at default. Cufflinks 2.2.1 was used to determine differential expression. 
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Mouse breeding. 
Tbx18-null animals used in the RNA-Seq experiment contain a H2B:GFP knock-in to the 
Tbx18 locus (Cai et al. 2008). The Tbx18Cre mouse is a gift from Syliva Evans. These animals 
were bread onto B6C3-F1 hybrid background because genetic background appears to influence 
phenotype severity (See Bolt et al. 2014). Animal work described in this study was carried out in 
strict accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The protocol was approved by the Institutional 
Animal Care and Use Committee of the University of Illinois (Animal Assurance Number: 
A3118-01; approved IACUC protocol number 11030) 
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Figures and Tables. 
 
 
Figure 3.1. Expression of Tbx18 in the urogenital sinus and final destination of Tbx18-
expressing cells. (A) Relative expression profile for Tbx18 in mouse prostate development by 
RT-qPCR. For each stage n ≥ 3, error bars are SEM. Tbx18 mRNA is detectable in the UGS as 
early as E15.5. The transcript is detected at increasing levels up to P3 and then levels fall 
considerably through adolescence. (B) TBX18 immunohistochemistry on wild type urogenital 
sinuses at E16.5, 18.5, and P3 demonstrate that TBX18 is expressed in the urogenital 
mesenchyme proximal to the adjacent prostate epithelium. (C) Tbx18 lineage tracing in the post-
natal prostate shows that daughter cells of Tbx18-positive urogenital mesenchyme contribute 
significantly to the prostate stromal layer. GFP expressing cells initially contribute heavily to the 
prostate stroma, but these cells are progressively lost as the prostate matures. 
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Figure 3.2. The urogenital sinus phenotypes in Tbx18-mutant animals. Hematoxylin and Eosin 
stains of wild type and Tbx18GFP/GFP and 12Gso/Tbx18- urogenital sinuses at P0. The 
disorganized condensing mesenchyme is indicated with black dashed lines. Mutants display 
morphologically normal UGSs at E16 (not shown). By P0 the urogenital epithelium is displaying 
roughened luminal surface with an increase in epithelial layer thickness. The UGS mesenchyme 
shows reduced numbers of condensed mesenchyme proximal to the nascent buds. 
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Table 3.1. UGS RNA-Seq GO BP table. Top scoring categories for E16.5 and E18.5 whole 
urogenital sinus RNA-Seq differentially expressed genes. Bold terms are gene ontology 
biological process categories. Under each category are a selection of differentially expressed 
genes and their associated log2 fold changes (FC).  
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Figure 3.3. KI67 proliferation and TUNEL apoptosis in the embryonic urogenital sinus. 
Proliferating cells stained with KI67 showed no difference between mutants and wild types at 
E16.5, and no difference in apoptosis. At P0, KI67 is reduced in Tbx18-null and 12Gso/Tbx18- 
heterozygotes in the urogenital sinus epithelium and mesenchyme. TUNEL staining at P0 
showed a strong increase in the amount of apoptosis in UGS-M adjacent to the UGS-E, with 
strongest staining in the ventral mesenchyme and the proximal dorsal mesenchyme. 
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Figure 3.4 
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Figure 3.4 (cont.). Adult prostate phenotype in 12Gso prostates. Hemotoxylin and Eosin 
staining of five week old 12Gso/Tbx18- compound heterozygote ventral prostates and wild type 
control. Scale bar is 100um. Higher magnifications of. 12Gso mutants display a massive increase 
in stromal thickness, with reduced muscle strand orientation compared to wild types. Mutant 
ventral prostate epithelia also displays compaction and reduced organization. SOX9 expression is 
maintained at high levels in the epithelium of 12Gso mutants. Quantification of the prostate 
stromal thickness (measured in um), nuclei counts, and the ratio of the number of nuclei per 
stromal thickness. Histograms are the sample mean (20 measurements for each) with error bars 
representing the Standard Error of the Mean. 
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Abstract: 
 The T-box transcription factor TBX18 is vital to the development of multiple organ 
systems including the axial skeleton, heart and urogenital tissues. Previous studies of this gene 
have identified specific interaction partners and a binding site preference for TBX18 but genome 
wide target genes have not been identified. We used a custom TBX18 antibody to detect TBX18 
protein binding sites with chromatin immunoprecipitation in mouse mesenchymal and epithelial 
cell types. From this ChIP study we also were able to identify a TBX18 binding site motif. We 
also carried out siRNA knockdown experiments in the same cells followed by expression arrays, 
allowing us to identify direct downstream target genes for TBX18. Additionally, we profiled 
genome-wide expression changes in Tbx18-null embryos to evaluate in vivo targets. These data 
reveal that TBX18 directly regulates genes controlling cell cycle, apoptosis, and extracellular 
matrix formation. This study represents the first look at direct TBX18 transcriptional targets and 
binding sites at the genomic level, and sheds new light on the complex roles of this T-box 
transcription factor in development. 
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Introduction: 
 The T-box transcription factors (TFs) are members of an ancient family of DNA binding 
proteins found across metazoa and some fungi (Showell et al. 2004; Degnan et al. 2009; Sebé-
Pedrós and Ariza-Cosano 2013). T-box proteins are expressed in multiple stages of development 
from the oocyte through gastrulation and organogenesis, and in the adult (King et al. 2006; 
Showell et al. 2004; Papaioannou 2014). These TF proteins can act as transcriptional activators 
or repressors, and some have been shown to be capable of both activities, depending upon the 
presence of interacting modifiers and partners (Beima et al. 2006). For example, interactions 
with the Groucho/TLE-associated protein RIPPLY have been shown to convert the zebrafish 
TBX24 from a transcriptional activator to a repressor (Kawamura et al. 2008).  
 The T-box gene Tbx18 is expressed broadly in mammalian mesenchymal cells, with a 
dynamic pattern of transcription that changes dramatically throughout mouse development 
(Kraus et al. 2001). The importance of Tbx18 activity in these diverse tissues is supported by the 
variety of apparently unrelated phenotypes associated with null mutations in mice. Most 
obviously, Tbx18 null mutants display striking abnormalities of the axial skeleton due to a failure 
to maintain somite polarity (Bussen et al. 2004). During somitogenesis, Tbx18 is expressed in the 
anterior somite segment. Later it is confined to the anterior lateral sclerotome, where it acts as an 
anti-apoptotic factor, maintaining cell density, and acting cooperatively with paired box TF 
PAX3, TBX18 acts to resist invasion by suppressing proliferation of posterior compartment cells 
(Farin et al. 2008). As a result, Tbx18-null mutants present reduced vertebrae polarity and 
overgrowths of the vertebral portions derived from the posterior somite, mainly affecting the 
pedicles and proximal ribs (Bussen et al. 2004). 
 Tbx18 is also required for development of the ureter. Tbx18 expression is detected early in 
the urogenital ridge, and continues in the nephrogenic mesenchyme extending from the 
mesonephros to the metanephros (Kraus et al. 2001; Airik et al. 2006; Bohnenpoll et al. 2013; 
Bolt et al. 2014). Tbx18-positive metanephric mesenchyme cells begin to condense around the 
ureter epithelium around embryonic day 11.5, and through inductive signaling processes 
mediated by Sox9 expression in the mesenchyme, the epithelial and mesenchymal layers 
proliferate, resulting in the elongation of the ureter. Tbx18 appears to act cooperatively with Sox9 
in the ureter mesenchyme to control the formation of ECM components and differentiation of the 
proximal ureter mesenchyme into smooth muscle cells (Airik et al. 2010). In the absence of 
	   
 
 
80 
TBX18, the mesenchymal cells fail to coalesce around the epithelium leaving the shortened 
ureter incapable of conducting urine from the kidney to the bladder (Airik et al. 2006; Bolt et al. 
2014).  
 Tbx18 is also expressed at high levels within mesothelial cells in the proepicardium and 
epicardium (Kraus et al. 2001) and plays a critical role in development and proliferation of cells 
in the head portion of the sinoatrial node (Wiese et al. 2009). While the developmental 
consequences of Tbx18 deficiency in these tissues is well documented and some interacting 
proteins and potential target genes have been elucidated, very little is known about the molecular 
programs that this TF protein regulates in these diverse cell types and tissues. Does Tbx18 
regulate different targets and processes in different cell environments, or does it regulate the 
same sets of targets, but in different patterns, within mesenchymal, epithelial, and other types of 
progenitor cells? 
 T-box gene family members are very similar in amino acid sequence and encode proteins 
with a highly conserved DNA binding domain (the T-box domain). Through this domain the T-
box protein recognizes and binds some variation of the T-half site DNA sequence, (5’-
AGGTGTGA-3’) with sequence variations specific to individual T-box proteins (1993; Farin et 
al. 2007; Macindoe et al. 2009). In vitro selection methods have confirmed that TBX18 and its 
closest paralogue TBX15 preferentially bind a variation of this T-half site (Farin et al. 2007). 
However, like most T-box proteins, TBX18 binding sites have not been determined genome-
wide in living cells or tissues.   
 To identify direct target genes for TBX18, we generated a custom antibody to the mouse 
TBX18 protein and mapped DNA binding sites in mouse epithelial and mesenchymal cell types 
by chromatin immunoprecipitation (ChIP). We coupled these studies with expression analysis of 
mRNA collected from the same cell lines after Tbx18 siRNA knockdown. To place these cell-
based studies in a developmental context we also generated expression arrays to compare mRNA 
from Tbx18–null mutant mouse embryos and normal litter mates. We found distinct roles for 
Tbx18 in the regulation of developmental pathways and cell cycle regulation in different cell 
types and identify an extended palindromic version of the T-box half-site motif that TBX18 
preferentially recognizes in mouse cells. 
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Methods: 
Antibody design. 
 An N-terminal region of the TBX18 amino acid sequence (qqqlqkkrrklateea) was selected 
based on antigenic properties and the low degree of sequence homology to other T-box proteins. 
Standard methods were used in the generation of a rabbit polyclonal antibody using a KLH 
carrier. We used standard Western blot techniques to test the antibody’s specificity and to 
identify cell types that express the protein. Thirteen micrograms at a concentration of 1ug/ml of 
antibody was used. 
 
ChIP-Chip. 
 Mouse C2C12 and M15 cells were obtained from the American Type Culture Collection 
(ATCC) and the European Collection of Cell Cultures (ECACC) respectively, and cultured as 
recommended by the providers in T75cm2 flasks. Cells were cross-linked in 1% formaldehyde 
for 7 minutes and 5 minutes respectively at 37°C.  ChIP-ready cell pellets were then stored at -
80º prior to sonication.  
 Chromatin immunoprecipitation was performed using the Millipore ChIP assay kit (cat#17-
295). Tbx18 was immunoprecipitated with 30µg of our anti-TBX18 antibody, and Santa Cruz 
Biotechnology goat-anti-rabbit IgG (sc-2027). Invitrogen Protein-G Dynabeads (cat#100.09D) 
were used to isolate antibody-bound DNA-protein complexes as detailed in the Millipore ChIP 
protocol.  ChIP-enriched DNA was amplified with Sigma-Aldrich GenomePlex whole genome 
amplification kit (WGA2). Post-amplification DNA was cleaned using Promega Wizard-SV 
cleanup kit.  
 WGA products were also prepared from an equivalent amount of genomic input DNA and 
both samples were labeled with Nimblegen dual-color DNA labeling kit. The labeled samples 
were hybridized to mouse Mm8 2.1M Deluxe Promoter Arrays and washed using a Maui 
Hybridization system with Nimblegen buffers according to methods suggested by the 
manufacturer. The arrays were scanned using a GenePix 4000B scanner in GenePix Pro 6.1 
software and peaks were identified using Nimblescan 2.6. We mapped peaks to locations to 
coordinates of flanking or nearest neighboring genes for further analysis. 
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siRNA Knockdown. 
 Small interfering RNA (siRNA) knockdown experiments were performed using the 
HiPerFect Transfection Reagent (Qiagen) as recommended by the manufacturer. Qiagen siRNAs 
for Tbx18 (Cat#SI01443351, SI01443358, SI01443365, SI01443372) were experimentally 
optimized at 1nM for >55% knockdown (see supplementary data). Cells were also treated with a 
negative control siRNA (Qiagen, # 1027280) under the same conditions. RNA was collected 
from cells treated with siRNA and HiPerFect for 32 hours using the Trizol reagent (Invitrogen). 
Invitrogen SuperScript III was used to reverse-transcribe RNA. Tbx18 knockdown efficiency 
was determined using quantitative reverse transcript PCR (qRT-PCR) with Tbx18-specific 
Qiagen primers (Cat#QT00133140) in SYBR green amplification buffer (ABI # 4368577). 
Mouse Sdha qRT-PCR primers (PrimerBankID# 54607097b1) were used as a control for 
normalization. An Applied Biosciences 7900HT thermocycler was used for qRT-PCR 
measurements.  
 After confirmation of Tbx18 knockdown, the total RNA samples isolated from siRNA-
treated cells and cells treated with the negative control were labeled and hybridized at the 
University of Illinois microarray center to Affymetrix 430A 2.0 (C2C12) and Affymetrix Gene 
ST1.0 microarrays (for M15 samples), according to manufacturer’s instructions. The microarray 
data were analyzed using Bioconductor software packages (http://www.bioconductor.org), 
essentially as described (Nowick et al., 2009).   
 
QPCR Target gene validation. 
 Putative targets of TBX18, identified as genes that were differentially expressed upon 
siRNA treatment and either harboring or directly flanking TBX18 binding sites identified by 
ChIP-chip, were selected for validation by qRT-PCR and quantitative PCR (qPCR) respectively. 
Primer sequences and sources are detailed in the Supplemental Text. RNA from siRNA 
experiments and DNA from chIP experiments were amplified in SYBR-green buffer. The ΔΔCt 
method was employed to establish quantity differences. 
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Results: 
Validation of the TBX18 antibody. 
 To map locations of TBX18 protein binding we generated a custom antibody to a unique 
N-terminal region of the protein (see Methods). We screened RNA from multiple mouse cell 
types for Tbx18 mRNA by RT-PCR (not shown), and selected two cell types that express Tbx18 
at robust levels: M15, a cell line derived from the mesonephric region of the nephrogenic cord 
with mesenchymal properties at sub-confluency and epithelial properties at confluency (Larsson 
et al. 1995; Vuononvirta et al. 2009) and C2C12, a cell line derived from skeletal muscle that is 
frequently used as a myoblast model but that can be differentiated to myotubes, smooth muscle, 
adipocytes, or osteoblast lineages and has properties similar to mesenchymal stem cells (Yaffe 
and Saxel 1977; Fux 2004). For these experiments, C2C12 was used in the sub-confluent state 
and M15 was used in the confluent state. We then used our antibody to detect the TBX18 protein 
by Western blot in both M15 and C2C12 nuclear protein extracts. The antibody detected a single 
protein of ~65kDa matching the predicted weight (Figure 4.1A). We also performed 
immunocytochemistry with the TBX18 antibody in C2C12 and M15 cells and found staining to 
be mostly nuclear in C2C12 with some cytoplasmic staining. In M15 we found the antibody 
detects the TBX18 protein in the nucleus as well as strong staining in the cytoplasm (Figure 
4.1B). 
  
Gene expression differences after knockdown of Tbx18 mRNA. 
 To identify genes that are differentially expressed after Tbx18 knockdown, we generated 
RNA samples from the siRNA-treated C2C12 and M15 cells and tested global gene expression 
using microarrays.  In C2C12 cells, 642 genes were up-regulated and 573 were down-regulated 
upon Tbx18 knockdown (p<0.05, FC>±1.5)(Table 4.S1). In M15 cells, 2213 genes were up-
regulated and 2202 were down-regulated in Tbx18-depleted cells (p<0.05, FC>±1.5) (Table 
4.S2).  These genes lists were used for all subsequent analyses.  
 We analyzed the differentially expressed gene (DEG) sets (Tables 4.S1 and 4.S2) from the 
different cell types using the DAVID functional annotation tool to identify enriched Gene 
Ontology Biological Process terms (Huang et al. 2008). In C2C12, down-regulated DEGs (genes 
that are normally activated by TBX18) displayed a significant enrichment for genes involved cell 
cycle control (p-value 1.1E-29), mitosis, and DNA damage repair among others (Table 4.1A). By 
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contrast, proton transport, aminoglycan metabolic processes, and extracellular matrix 
organization were highly represented in the up-regulated genes (normally repressed by TBX18). 
In M15 cells, transcriptional processes, vascular development, and others were found to be 
reduced in the absence of TBX18. In sharp contrast to C2C12 cells, in M15, cell cycle regulation 
and DNA damage response were among the activated categories (Table 4.1B). 
 Interestingly, the most highly up- or down-regulated in the two experiments included 
several common genes. For example, chemokine genes, Cxcl1, Cxcl5, and signaling components, 
Ogn (encoding osteoglycin), Sfrp2, Sfrp4 (secreted frizzled-related proteins 2 and 4) and Fgf7 
(fibroblast growth factor 7) were among the most highly down-regulated genes in siRNA-treated 
cells of both types. By contrast, Dpt (dermopontin) and interacting gene, Dcn (decorin), which 
are both ECM components involved in TGFβ signaling, and Postn (periostin) were among the 
most highly up-regulated in both experiments (Table 4.S1 and 4.S2). 
 Next we determined the set of genes that were differentially expressed in both cell types, 
and compared how they changed between epithelial and mesenchymal cells upon knockdown of 
Tbx18. We identified a total of 589 genes that appeared in both DEG lists, including 274 genes 
that were up-regulated after siRNA knockdown in both cells, 145 genes that were down-
regulated by siRNA treatment in both cells, and 170 genes that displayed altered expression in 
both cell types but were affected oppositely in them (Table 4.S4). 
 We then performed the same Gene Ontology analysis on the lists of genes that were 
positively, negatively, or oppositely changed between cell types. Lipid metabolic processes, 
neural crest development and mesenchyme differentiation were some of the top scoring (small p-
values) in genes that were up-regulated in both cell types upon Tbx18 knockdown. Multiple 
tissue developmental processes, cell adhesion, and Wnt signaling were highly enriched in the 
genes that were down-regulated in both cell types. The most telling of these groupings, however, 
included genes that were oppositely directed in the two cell types upon knockdown (Table 4.S4). 
Functional clustering of these genes identified cell cycle (1.0E-4) and cell division (1.4E-4) 
genes as especially enriched in this data set. Most notably, genes that were significantly down-
regulated in mesenchymal C2C12 cells, but up-regulated in epithelial M15 cells after Tbx18 
ablation were very highly enriched in genes associated with cell cycle, DNA replication, and 
chromosome organization indicating that those functions are oppositely regulated by Tbx18 in 
those cells (Table 4.S4). In particular, some of the genes that stand out as the most highly 
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differentially expressed and are known interactors in the Retinoblastoma cell cycle regulation 
pathway: E2f2 and E2f7 (Rb1-regulated TFs) Ccna2, Ccnd1 (cyclins – Rb1 regulators), Sp1, 
Cdk1, Rbbp8 and Rbl1 (all of which are Rb1 interactors)(Table 4.1A-B)(Vermeulen et al. 2003; 
Giacinti and Giordano 2006).  
 
Expression analysis in Tbx18 null-mutant Embryos. 
 Tbx18 is expressed in many tissues during development with organismic roles that our cell 
culture-based studies may not have captured. A full comparison of our results to in vivo 
expression would require separate analysis of multiple individual embryonic cell types.  
However, as a first step to complement our analysis in C2C12 and M15 cells, we generated RNA 
from whole E11.5 Tbx18 null-mutant embryos and littermate controls and performed expression 
arrays comparing these samples. At this developmental stage, Tbx18 is expressed at relatively 
high levels in a few cell types, most prominently in the proepicardium and mesenchyme of the 
urogenital tract, somites of the tailbud, developing ear, limb buds, and vibrissae (Kraus et al. 
2001). The DEGs identified in these microarrays (Table 4.S3) revealed functional enrichment in 
several categories (Table 4.1C). Cell surface signaling, antigen presentation, and heart 
development were among the down-regulated terms in the mutant embryos; by contrast, 
transcription, chromatin modification, skeletal development, and Wnt signaling were identified 
as enriched in the up-regulated genes (Table 4.1C).   
 We then compared the results from the Tbx18 null mutant embryos to our siRNA 
knockdown data. A total of 81 genes were up-regulated in both siRNA-treated C2C12 cells and 
the mutant embryos, 58 genes were commonly down-regulated, and 126 genes were oppositely 
expressed in the cell line compared to whole mutant embryos. In the overlap between M15 
siRNA knockdown and the knockout embryos there were 763 genes that were commonly up-
regulated, 502 commonly down-regulated genes, and 716 genes that were differentially 
expressed in opposite directions (Table 4.S5).  
 We then dissected these lists into genes that were similarly changed between the cell lines 
and the embryos, or oppositely expressed in the cell line and embryo arrays. Cell matrix 
adhesion and protein dephosphorylation were similarly up-regulated in siRNA-treated C2C12 
cells and the Tbx18-/- embryos. Fifty-eight genes were commonly down-regulated in Tbx18-
depleted C2C12 cells and embryos, but no functional categories were significantly represented 
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among those gene. When we examined genes that were down-regulated in si-treated C2C12 cells 
and up-regulated in the Tbx18 null mutant embryos, multiple developmental programs, cell 
motility, and cell-cycle process genes were found to be enriched. In the DEGs that were common 
to the M15 knockdown and null-embryo lists, we found enrichment for genes involved in cell 
cycle, mitosis, transcription regulation and vascular development to be up-regulated in both 
experiments. In the genes that were down-regulated in both of these experiments, we identified 
enrichment for functions including negative regulation of apoptosis, cell proliferation and cell 
cycle. Finally, in comparison of genes that were oppositely affected in Tbx18-depleted M15 cells 
and E11.5 embryos, DAVID identified skeletal development, transcription regulation, and cell 
morphogenesis among the top scoring biological processes (Table 4.S5). 
 
Identifying protein binding sites with TBX18 ChIP. 
 To identify TBX18 binding sites, we used ChIP to enrich for binding regions from 
duplicate chromatin preparations from both C2C12 and M15 cells. We identified TBX18 binding 
regions by hybridizing the ChIP-enriched material from each preparation to Nimblegen 2.1M 
Deluxe Promoter Arrays, with tiled oligonucleotides that span 11.2 Kb regions surrounding 
promoters of 24,507 annotated mouse genes and 249 miRNA loci, as well as 15,963 CpG 
islands. From these experiments we identified 2073 reproducible peaks in the duplicate C2C12 
experiments, and 2732 peaks in M15 (determined as peaks with FDR< 0.05). From these 
independently identified peaks, 1127 overlapping peak regions were identified in chromatin from 
C2C12 and M15 cells.  
 
Differential gene expression and ChIP-Chip Overlap. 
 Next we examined overlap between the TBX18 binding sites and the differentially 
expressed genes in both cell types to identify a set of genes that are potentially the direct targets 
of TBX18 activity. First, we assigned peaks either within a gene (intron or exon) or between two 
nearest genes, if intergenic, matching coordinates of the peaks to those of annotated mouse 
Refseq loci. Then we identified all DEGs that either contain or are directly flanked by intergenic 
ChIP peaks. We found 231 C2C12 DEGs associated with 345 TBX18 peak regions in C2C12 
cells, and 967 genes containing or flanking 1326 peaks in the M15 cells (Table 4.S6 and 4.S7).  
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 These genes, which contain or directly flank TBX18 ChIP peaks, represent putative direct 
targets of the T-box protein.  In functional analysis of these direct-target genes in M15 cells, we 
identified cell signaling pathways, skeletal development, and cell migration among the enriched 
pathways. In the up-regulated sets, M-phase and cell division, microtubule organization, and 
apoptosis were significantly enriched (Table 4.S7). In stark contrast, cell division and cell cycle, 
apoptosis, and cellular signaling pathways were enriched in the down-regulated genes in C2C12 
cells, while pattern specification was the only category enriched with a significant p-value in the 
up-regulated gene set (Table 4.S6). 
 We then sought to identify functions for the DEGs identified in the knockout embryos that 
harbored or flanked M15 and C2C12 ChIP peaks. We found 363 Tbx18-/- DEGs with 510 
corresponding ChIP peaks in C2C12 (Table 4.S8). The functional terms enriched in these genes 
were very similar to those identified in the Tbx18-/- embryo expression analysis overall, and 
included heart development, immunity, transcription, and cell signaling (Table 4.2). When we 
overlapped the null-embryo DEGs with the M15 ChIP-chip peaks we found 442 differentially 
expressed genes corresponding to 602 peaks (Table 4.S9). Regulation of Tumor Necrosis Factor, 
cardiac development, and intracellular signaling were among the enriched categories in the 
down-regulated genes. Several signaling mechanisms, transcription regulation, and sex 
development were found enriched in the up-regulated genes. 
 
TBX18 Binding Site Motif. 
 We examined ChIP peaks identified in M15 and C2C12 cells to identify a TBX18 binding 
site motif. We used DNA sequence of peaks detected with false discovery rate (FDR) < 0.0001 
present in both M15 and C2C12 cells in the CisFinder motif analysis program (Sharov and Ko 
2009) to identify over-represented motifs sequences in this collection of peaks. From this search 
we identified a sequence with significant similarity to a TBX18 binding site previously identified 
in in vitro binding experiments (Farin et al. 2007). The binding site determined in vitro contained 
a nineteen base sequence containing a partial palindrome. The sequence identified in our ChIP-
chip studies is identical at eleven of these nineteen nucleotides, but varies considerably near the 
center of the binding site (Figure 4.2). 
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Validation of Tbx18 Targets. 
 We chose a selection of putative TBX18 direct targets from the overlap between DEG and 
ChIP datasets (Table 4.3). We validated ChIP enrichment for the selected peaks by qPCR, 
measuring enrichment after TBX18 ChIP compared to mock ChIP controls, after independently 
conducted ChIP pulldown experiments in the same cell types. DEG expression was validated by 
qRT-PCR comparisons between Tbx18-specific and negative control siRNA-treated cells and in 
TBX18-null embryos by comparison with wild type embryos.   
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Discussion: 
Tbx18 regulates multiple genetic pathways. 
 Tbx18 null mutations give rise to severe phenotypes in several tissue types that combine to 
produce lethal effects at perinatal stages of development (Bussen et al. 2004; Airik et al. 2006; 
Cai et al. 2008; Christoffels 2006). These complex, pleiotropic phenotypes bespeak a complex 
function for the gene, potentially involving different transcriptional targets or transcriptional 
effects in each tissue. However, to date, the identification of TBX18 transcriptional targets has 
been limited to only a handful of candidate genes. To identify Tbx18 regulatory activities on a 
genome-wide scale, we generated and tested a unique TBX18 antibody and used this reagent to 
map binding sites in mouse mesenchymal and epithelial cell types that express the TBX18 
protein with ChIP.  
 To model the in vivo activity of TBX18 in different tissues we used two cell lines 
representing mesenchymal and epithelial cell types. M15 cells are commonly characterized as 
epithelioid in nature, but recent work has shown these cells have a propensity to undergo 
mesenchymal-epithelial transition in a confluency-dependent manner, although our expression 
data suggests M15 never fully transitions to epithelium even at high confluency. Additionally, 
we used C2C12 mesenchymal cells because of their potential to be induced to other cell types 
such as smooth muscle (Fux 2004). Together, these cell types are intended to represent Tbx18-
expressing tissues with different transcriptional activities and biological outcomes. As such, this 
study reveals the involvement of Tbx18 in multiple genetic pathways, and indicate that the TF 
protein acts to regulate these biological processes distinctly in mesenchymal and epithelial cells. 
 Previous studies have shown that Tbx18 serves to regulate other transcription factors, 
including Sox9 in the developing ureteric mesenchyme (Airik et al. 2010). Our data confirm Sox9 
as a direct TBX18 target and show that this TF is significantly up-regulated after TBX18 
ablation. Therefore, in the tested cell types at least, Sox9 is specifically repressed by the action of 
TBX18. This differs from the reported activity of TBX18 activating Sox9 in ureter development. 
Reasons for the difference are unclear but may result from biological differences of the different 
assays used. For example, TBX18 may be a repressor of Sox9 in the undifferentiated 
mesenchyme, until a signal from the adjacent epithelium alters the activity of TBX18 in the cells 
directly adjacent to the ureter; the nascent smooth muscle.  
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 The data presented here also reveal roles for Tbx18 in novel functional pathways, including 
cytokine signaling (through direct target gene such as Cxcl12, Ccrl1, and Cxxc5), ECM 
organization and ECM component signaling (through targets including Dcn, Lum and Vcan), 
steroid biosynthesis (Hsd11b1, Hsd11b2, and Hsd17b12) and cell cycle regulation.  Significant 
enrichment for genes involved in blood vessel and bone development were also detected in the 
target gene set, fitting well with known roles of Tbx18 in development of the skeleton and heart 
(Cai et al. 2008; Rosemann et al. 2003; Haraguchi et al. 2014). Additionally, some of these 
pathways may be indicative of a role for Tbx18 in tissues and processes that have not yet been 
characterized. 
 Most of these genetic programs are commonly regulated by Tbx18 in both mesenchymal 
and epithelial cells: TBX18 targets in both cell types were associated with transcription, and 
apoptosis, consistent with early phenotypic studies that identified those same processes as 
defective in Tbx18-null mice (Airik et al. 2006; Bussen et al. 2004). However, we also identified 
gene targets and pathways that are oppositely affected by TBX18 binding in the C2C12 and M15 
cells.   
 Specifically, the genes that are oppositely affected by Tbx18 knockdown in the two cell 
types are very highly enriched for functions related to cell cycle regulation and cell proliferation; 
genes of this functional class were down-regulated in C2C12 mesenchymal cells indicating 
Tbx18 activation in that cell type, while many of the same target genes were identified as 
negative targets in epithelial M15 cells.  Several of these cell-cycle regulators were associated 
with TBX18 binding sites in one or both cell types suggesting that they are directly, but 
oppositely, regulated by the binding of TBX18.   
 Together these suggest that while TBX18 binding sites may be largely available in the two 
cell populations, protein binding can translate into different outcomes depending on the cell 
environment. We think this effect is likely due to recruitment of the different binding partners 
that TBX18 may encounter in mesenchymal compared to epithelial cell types; we hypothesize 
that therefore, binding-partner availability will likely affect TBX18 protein function during 
different developmental stages as well.  
 In support of this hypothesis, work in T-bet (Tbx21) has shown that this particular T-box 
can have activating or repressing activity dependent on the cell type (Beima et al. 2006). T-bet 
and other T-box proteins have been shown to contain both activation and repression domains 
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(Stennard et al. 2003) suggesting that activation or repression of target genes is context 
dependent. Finally, the Groucho/TLE-associated Ripply converts the zebrafish T-box TBX24 
from an activator to a repressor (Kawamura et al. 2008) in the same cell type in a promoter-
context dependent manner. Similarly, TBX18 has been shown to physically interact with 
Groucho-related-genes (Grgs) but there is currently no data directly testing for activator and 
repressor function of this gene (Farin et al. 2007; Jennings and Ish-Horowicz 2008). 
Additionally, while no work has looked to determine if T-box proteins switch regulatory 
activities on the same targets before and after developmental transitions such as Mesenchymal-
Epithelial Transition, this remains a possibility. These ideas support the hypothesis that TBX18 
may regulate target genes differently in different cell types but more functional data is needed to 
support this hypothesis. 
 
TBX18 binding site. 
 Previous studies, using in vitro selection methods, have demonstrated that TBX18 binds a 
variation of the T-box motif (Farin et al. 2007). However, the protein’s binding preference in 
vivo may differ due to the presence of competing factors, cofactors and epigenetic states. Indeed, 
studies involving T-box proteins have found that most bind sequences that are similar to 
canonical T-box half-site in vivo, but with some significant protein-specific differences (Mori et 
al. 2006; Shen et al. 2011; He et al. 2011). 
 Similarly, our data shows that TBX18 binds in vivo to a motif that includes a direct repeat 
of a sequence that is a variation of the canonical T-half site (Figure 4.2). The sequence we 
identified shares many similarities to the TBX18 binding motif identified in in vitro studies 
(Farin et al. 2007). Palindromic or direct repeat binding sites have been proposed in studies of 
other T-box proteins, but the presence of these sites is not supported by in vivo data suggesting 
that they may be an in vitro artifact. In deed, it appears that most T-box proteins bind DNA as a 
monomer in vivo (Papaioannou 2014). However, our data provides new evidence that this 
structure is in fact a preferred binding sequence for the TBX18 protein in vivo. These data could 
indicate homo-dimerization, but could also reveal the footprint of an interaction between TBX18 
protein and another T-box protein at many preferred binding sites in C2C12 and M15 cells. This 
is supported by evidence that T-box proteins TBX6, TBX15, and TBX18 compete for a binding 
site in a Dll1 promoter assay (Wehn and Chapman 2010), and TBX18 and TBX5 have been 
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shown to compete for binding in the Nppa promoter (Farin et al. 2007). 
 
Conclusion. 
 Together these studies provide significant new insights to the regulatory activities of 
TBX18. Our data show that the protein serves as a direct regulator of multiple transcription 
factor genes as well as signaling molecules, ECM proteins and cell cycle regulators.  While most 
of these targets are shared in different cell types, Tbx18 had strikingly opposite effects on genes 
controlling cell division and proliferation in the mesenchymal and epithelial cells.  We 
hypothesize that while preferred locations of TBX18 binding sites are largely fixed, the outcome 
of TF binding is modulated by interactions with regulatory partners that differ depending on cell 
type, developmental stage, and cell environment. With access to a specific TBX18 antibody and 
the identities of direct target genes that are shared in divergent tissues, we can now examine 
these hypotheses in the context of primary cells in developing tissues.  
 
 
 
  
	   
 
 
93 
References: 
Airik R, Bussen M, Singh MK, Petry M, Kispert A. 2006. Tbx18 regulates the development of 
the ureteral mesenchyme. Journal of Clinical Investigation 116: 663–674. 
Airik R, Trowe M-O, Foik A, Farin HF, Petry M, Schuster-Gossler K, Schweizer M, Scherer G, 
Kist R, Kispert A. 2010. Hydroureternephrosis due to loss of Sox9-regulated smooth muscle 
cell differentiation of the ureteric mesenchyme. Human Molecular Genetics 19: 4918–4929. 
Beima KM, Miazgowicz MM, Lewis MD, Yan PS, Huang TH-M, Weinmann AS. 2006. T-bet 
Binding to Newly Identified Target Gene Promoters Is Cell Type-independent but Results in 
Variable Context-dependent Functional Effects. Journal of Biological Chemistry 281: 
11992–12000. 
Bohnenpoll T, Bettenhausen E, Weiss A-C, Foik AB, Trowe M-O, Blank P, Airik R, Kispert A. 
2013. Tbx18 expression demarcates multipotent precursor populations in the developing 
urogenital system but is exclusively required within the ureteric mesenchymal lineage to 
suppress a renal stromal fate. Developmental Biology 380: 25–36. 
Bolt CC, Elso CM, Lu X, Pan F, Kispert A, Stubbs L. 2014. A distant downstream enhancer 
directs essential expression of Tbx18 in urogenital tissues. Developmental Biology 392: 483–
493. 
Bussen M, Petry M, Schuster-Gossler K, Leitges M, Gossler A, Kispert A. 2004. The T-box 
transcription factor Tbx18 maintains the separation of anterior and posterior somite 
compartments. Genes & Development 18: 1209–1221. 
http://www.genesdev.org/cgi/doi/10.1101/gad.300104. 
Cai C-L, Martin JC, Sun Y, Cui L, Wang L, Ouyang K, Yang L, Bu L, Liang X, Zhang X, et al. 
2008. A myocardial lineage derives from Tbx18 epicardial cells. Nature 454: 104–108. 
Christoffels VM. 2006. Formation of the Venous Pole of the Heart From an Nkx2-5-Negative 
Precursor Population Requires Tbx18. Circulation Research 98: 1555–1563. 
Degnan BM, Vervoort M, Larroux C, Richards GS. 2009. Early evolution of metazoan 
transcription factors. Current Opinion in Genetics & Development 19: 591–599. 
Farin HF, Bussen M, Schmidt MK, Singh MK, Schuster-Gossler K, Kispert A. 2007. 
Transcriptional Repression by the T-box Proteins Tbx18 and Tbx15 Depends on Groucho 
Corepressors. Journal of Biological Chemistry 282: 25748–25759. 
Farin HF, Mansouri A, Petry M, Kispert A. 2008. T-box protein Tbx18 interacts with the paired 
box protein Pax3 in the development of the paraxial mesoderm. Journal of Biological 
Chemistry 283: 25372–25380. 
Fux C. 2004. Dual-regulated expression of C/EBP-  and BMP-2 enables differential 
differentiation of C2C12 cells into adipocytes and osteoblasts. Nucleic Acids Research 32: 
1e–1. 
	   
 
 
94 
Giacinti C, Giordano A. 2006. RB and cell cycle progression. Oncogene 25: 5220–5227. 
Haraguchi R, Kitazawa R, Kitazawa S. 2014. Epigenetic regulation of Tbx18 gene expression 
during endochondral bone formation. Cell Tissue Res 359: 503–512. 
He A, Kong SW, Ma Q, Pu WT. 2011. Co-occupancy by multiple cardiac transcription factors 
identifies transcriptional enhancers active in heart. Proceedings of the National Academy of 
Sciences 108: 5632–5637. 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078411/pdf/pnas.201016959.pdf. 
Huang DW, Sherman BT, Lempicki RA. 2008. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57. 
Jennings BH, Ish-Horowicz D. 2008. The Groucho/TLE/Grg family of transcriptional co-
repressors. Genome Biol 9: 205. 
Kawamura A, Koshida S, Takada S. 2008. Activator-to-repressor conversion of T-box 
transcription factors by the Ripply family of Groucho/TLE-associated mediators. Molecular 
and Cellular Biology 28: 3236–3244. 
King M, Arnold JS, Shanske A, Morrow BE. 2006. T-genes and limb bud development. Am J 
Med Genet 140A: 1407–1413. 
Kraus F, Haenig B, Kispert A. 2001. Cloning and expression analysis of the mouse T-box gene 
Tbx18. Mechanisms of Development 100: 83–86. 
Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van 
Heyningen V, Hastie ND. 1995. Subnuclear localization of WT1 in splicing or transcription 
factor domains is regulated by alternative splicing. Cell 81: 391–401. 
Macindoe I, Glockner L, Vukašin P, Stennard FA, Costa MW, Harvey RP, Mackay JP, Sunde M. 
2009. Conformational Stability and DNA Binding Specificity of the Cardiac T-Box 
Transcription Factor Tbx20. Journal of Molecular Biology 389: 606–618. 
Mori AD, Zhu Y, Vahora I, Nieman B, Koshiba-Takeuchi K, Davidson L, Pizard A, Seidman 
JG, Seidman CE, Chen XJ, et al. 2006. Tbx5-dependent rheostatic control of cardiac gene 
expression and morphogenesis. Developmental Biology 297: 566–586. 
Papaioannou VE. 2014. The T-box gene family: emerging roles in development, stem cells and 
cancer. Development 141: 3819–3833. 
Rosemann M, Kuosaite V, Nathrath M, Strom TM, Quintanilla-Martinez L, Richter T, Imai K, 
Atkinson MJ. 2003. Allelic imbalance at intragenic markers of Tbx18 is a hallmark of 
murine osteosarcoma. Carcinogenesis 24: 371–376. 
Sebé-Pedrós A, Ariza-Cosano A. 2013. Early evolution of the T-box transcription factor family. 
 
	   
 
 
95 
Sharov AA, Ko MSH. 2009. Exhaustive Search for Over-represented DNA Sequence Motifs 
with CisFinder. DNA Research 16: 261–273. 
Shen T, Aneas I, Sakabe N, Dirschinger RJ, Wang G, Smemo S, Westlund JM, Cheng H, Dalton 
N, Gu Y, et al. 2011. Tbx20 regulates a genetic program essential to adult mouse 
cardiomyocyte function. Journal of Clinical Investigation 121: 4640–4654. 
Showell C, Binder O, Conlon FL. 2004. T-box genes in early embryogenesis. Dev Dyn 229: 
201–218. 
Stennard FA, Costa MW, Elliott DA, Rankin S, Haast SJP, Lai D, McDonald LPA, Niederreither 
K, Dolle P, Bruneau BG, et al. 2003. Cardiac T-box factor Tbx20 directly interacts with 
Nkx2-5, GATA4, and GATA5 in regulation of gene expression in the developing heart. 
Developmental Biology 262: 206–224. 
Vermeulen K, Berneman ZN, Van Bockstaele DR. 2003. Cell cycle and apoptosis. Cell 
Proliferation 36: 165–175. 
Vuononvirta R, Sebire NJ, Messahel B, Perusinghe N, Reis-Filho JS, Pritchard-Jones K, Vujanic 
GM, Jones C. 2009. Expression of Hepatocyte Growth Factor and Its Receptor Met in 
Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development. 
Clinical Cancer Research 15: 2723–2730. 
Wehn AK, Chapman DL. 2010. Tbx18 and Tbx15 null-like phenotypes in mouse embryos 
expressing Tbx6 in somitic and lateral plate mesoderm. Developmental Biology 347: 404–
413. 
Wiese C, Grieskamp T, Airik R, Mommersteeg MTM, Gardiwal A, de Gier-de Vries C, 
Schuster-Gossler K, Moorman AFM, Kispert A, Christoffels VM. 2009. Formation of the 
Sinus Node Head and Differentiation of Sinus Node Myocardium Are Independently 
Regulated by Tbx18 and Tbx3. Circulation Research 104: 388–397. 
Yaffe D, Saxel O. 1977. Serial passaging and differentiation of myogenic cells isolated from 
dystrophic mouse muscle. Nature 270: 725–727. 
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=563524&retmode
=ref&cmd=prlinks. 
Kispert A, Hermmann B. 1993. The Brachyury gene encodes a novel DNA binding protein. The 
EMBO Journal 12: 3211-322.  
 	  
  
	   
 
 
96 
Figures and Tables. 
 
 
Figure 4.1. TBX18 westerns in C2C12 and M15 cells. (A) The TBX18 antibody detects a 
protein of roughly 65kD with high specificity, matching the predicted size for the protein. (B) 
TBX18 immunocytochemistry in C2C12 and M15 cells shows strong nuclear staining. 
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Figure 4.2. TBX18 binding site as determined in vivo. Using reproducible ChIP peaks in M15 
and C2C12 ChIP-chip experiments, we selected the peaks with the lowest FDRs (FDR<0.0001) 
to identify an in vivo TBX18 binding site. (A) A core motif of 13 base pairs was identified. (B) A 
larger extended motif was also identified from the same dataset. (C) The TBX18 binding site as 
determined using in vitro selection methods (Farin et al. 2007). Underlined bases are those with 
identity to our motif. (D) The Brachyury in vitro motif for comparison (Kispert et al. 1993).  
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Table 4.1A 
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Table 4.1B 
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Table 4.1C 
 
 
Table 4.1 (cont.). Selected Gene Ontology Biological Process terms that were enriched in Tbx18 
siRNA-mediated knockdown experiments in C2C12 (A), M15 cells (B), and E11.5 Tbx18-null 
embryos (C). Each list contains a selection of genes that are enriched in each experiment. 
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Table 4.2. Selected GO BP terms from putative direct targets of TBX18. Genes that were 
differentially expressed with TBX18 binding sites adjacent to them were used to identify 
enriched Biological Process terms.  
 
	   
 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Conclusion. 
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Summary: 
 The purpose of this work was to evaluate the role of Tbx18 in urogenital development by 
dissecting its cis-regulatory structure and determining its downstream influence. To do this we 
used the 12Gso mutation to identify a key Tbx18 enhancer responsible for expression in the 
urogenital system. We were also able to identify a novel role for Tbx18 in the development of the 
prostate, with the 12Gso loss-of-function phenotype capable of being a disease model for 
humans. Additionally, we were able to evaluate the genome-wide consequences of reduced 
Tbx18 expression in multiple model cell-types and tissues. On the whole, we found that loss of 
Tbx18 in the urogenital system leads to a tissue imbalance in the prostate stroma and epithelium, 
and a non-functional organ with tissue disorganization that is reminiscent of early-stage prostate 
cancer. In cell culture, TBX18 acts on potent downstream pro-proliferation factors providing a 
key link to a variety of phenotypes in multiple tissues that have so far appeared to be unrelated. 
Together, this work contributes to our understanding of how the urogenital system is patterned in 
development and provides the basis for useful studies in the formation of human prostate 
pathologies. 
 
Synthesis: 
cis-regulation of the Tbx18 locus. 
 Our entryway to the study of Tbx18 came through a genetic screen for developmental 
phenotypes in mice. This screen was based on work by Dr. Walderico Generoso of Oakridge 
National Laboratory on a variety of mammalian DNA mutagens (Generoso 1969; 1973; Culiat et 
al. 1997). One of the lines of mice produced by W. Generoso and L. Stubbs, presented a 
recessive mutation that dramatically altered the development of the axial skeleton. These mice, 
referred to as 12Gso, have stunted growth and fail to thrive, with only a fraction of mutant 
animals surviving beyond neonatal stages. The 12Gso mutant animals also present a complex 
array of urinary and reproductive anomalies that were especially interesting to me. Upon closer 
inspection, we confirmed that the 12Gso mutation is a balanced reciprocal chromosome 
translocation that produces a hypomorphic allele of the Tbx18 gene (Chapter 2). 
 The 12Gso chromosome translocation on chromosome 9 is approximately 80kbp 
downstream from the 3’ end of Tbx18 (Chapter 2, Figure 2.3). The second chromosome involved 
in the 12Gso mutation is chromosome 4, where the breakpoint lies within the Abca1 ATP-
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dependent cholesterol efflux pump gene. Abca1 is expressed at high levels in the liver and 
kidneys but a loss-of-function mutation does not express skeletal or urogenital phenotypes (Attie 
et al. 2001; Christiansen-Weber et al. 2010). Using genetic complementation tests we 
definitively ruled out a role for the Abca1 gene in the phenotypes identified in 12Gso (Bolt et al. 
2014). On the other hand, we also showed that Tbx18 loss-of-function mutations do not 
complement 12Gso (Chapter 2, Figure 2.1 and 2.2), demonstrating that 12Gso is an allele of 
Tbx18. Double heterozygotes generated by crossing 12Gso to Tbx18 carrier mice display the 
malformed axial skeletons and ureters observed in both 12Gso translocation homozygotes and 
Tbx18-null homozygotes. Curiously however, 12Gso homozygotes and 12Gso/Tbx18-null double 
heterozygotes are capable of living into adulthood, while Tbx18-null animals are not (Chapter 2, 
Figures 1 and 2). 
 These complementation tests suggested that the 12Gso translocation disrupts a physical 
connection between a distal urogenital enhancer and the Tbx18 promoter that may influence gene 
expression in a tissue-specific manner, possibly explaining the longevity difference between 
mutant lines. This prompted our search for a distal regulatory element active in urogenital 
development. During the course of this study we were able to locate the responsible enhancer, 
which we refer to as ECR1, and test its function in a transgenic reporter system. This regulatory 
element ECR1, is spatially restricted to the developing urogenital system mesenchyme in a 
manner that matches native Tbx18 expression (Chapter 2, Figure 2.5). 
 The discovery of ECR1 and its expression pattern, including expression in the urogenital 
sinus mesenchyme (UGS-M), provided a strong suggestion to evaluate the prostate for 
phenotypes. When we did so, we observed that adult 12Gso/Tbx18- animals presented significant 
malformations of the ventral prostate gland (Chapter 3, Figure 3.2 and 3.4). Additionally, we 
observed a reduction but persistence of Tbx18 expression in the 12Gso UGS-M at embryonic 
stages concomitant with a reduction in condensed mesenchyme, which is prospective smooth 
muscle (Chapter 2, Figure 2.3, Chapter 3, Figure 3.2). The reduction in condensed mesenchyme 
in the UGS is very similar to the ureter where the mesenchyme and resulting smooth muscle 
forms undersized in Tbx18 mutants. Paradoxically, in the prostate, the cells that replace the dying 
Tbx18 cells increase in size and appear to inappropriately influence the adjacent epithelium, 
which overgrows as well. 
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 When we evaluated the ECR1 enhancer and the Tbx18 promoter for conserved 
transcription factor binding sites that may be involved in these phenotypes, we found conserved 
binding sites for SOX9, PAX2, and the Wilms Tumor suppressor, WT1. Each of these three has 
been implicated in past studies to be interacting with TBX18 and have important roles in 
urogenital development (Bin Zeng et al. 2011; Airik et al. 2006). We then used antibodies 
directed against these proteins for chromatin immunoprecipitation in C2C12 mesenchymal 
myoblasts and found all three of these proteins to be significantly enriched at both the ECR1 
enhancer as well as the Tbx18 promoter (data not shown). Together, this indicates that these 
important developmental transcription factors are regulating the expression of Tbx18, and that 
the 12Gso translocation prevents ECR1 enhancer from activating the Tbx18 promoter at the 
appropriate time in urogenital development. This provides a basis for further research into the 
upstream activators of Tbx18. 
 In future studies, we plan to test for direct interaction between the Tbx18 promoter region 
and ECR1. To do this, we plan to identify active enhancers in the Tbx18 locus during urogenital 
sinus development by histone H3K27Ac and H3K4me3 chromatin immunoprecipitation, or 
through a new technique referred to as ATAC-Seq. This latter technique is less specific than 
histone modification ChIP, but rather allows for the identification of open chromatin that is not 
biased towards specific chromatin modifications (Buenrostro et al. 2013). One of the most 
important benefits of ATAC-Seq is that it can identify open chromatin in as few as ten thousand 
cells which can easily be obtained from a single urogenital sinus. These results will provide a list 
of putative open chromatin regions, which should be enriched for regional UGS enhancers. We 
can then test for the formation of chromatin loops between regulatory elements using variations 
of the Chromosome Conformation Capture technique such as 4C-Seq which uses a viewpoint 
such as a gene promoter to search for interactions between the promoter and enhancers in an 
unbiased way (van de Werken et al. 2012). 
 Together, these results and forthcoming experiments will provide excellent insight to the 
regulatory dynamics of the Tbx18 locus during urogenital sinus development. This large gene 
desert is likely to hold more regulatory secrets as well, such as the unidentified somite enhancer 
which is also separated from Tbx18 by 12Gso. There may also be additional unknown Tbx18 
phenotypes that are identifiable using 12Gso. In summary, the 12Gso mutation, which is tissue 
specific and hypomorphic, provides a novel tool for dissecting the cis-regulation of Tbx18, and 
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for studying the role of Tbx18 in post-natal development of the prostate. No other current Tbx18 
mutation model can facilitate those goals.  
 
The downstream influence of Tbx18. 
 Loss-of-function mutations to Tbx18 produce a variety of phenotypes in different tissues. 
For example, Tbx18-null animals are deaf, they have incompetent urinary systems, they have 
prostate hypertrophy, and possess a bewildering number of subtle cardiovascular defects (Airik 
et al. 2006; Trowe et al. 2010; Bolt et al. 2014; Bussen et al. 2004). Understanding how the loss 
of one gene can have such diverse phenotypic consequences has been an important underlying 
question in this work. To address this question, we used a number of cell types and tissues to 
assess the downstream targets of Tbx18 so that we may determine if Tbx18 regulates similar 
mechanisms in various cell types, or if it acts through diverse means.  
 By evaluating downstream targets of Tbx18 in two immortalized cell-types, C2C12 and 
M15, in addition to Tbx18-null and 12Gso homozygous embryos and urogenital sinuses we can 
conclude with some confidence what the impact of Tbx18 abrogation has in cells. We can break 
down the Tbx18 downstream targets into three categories: regulation of proliferation via cell 
cycle control, regulation of other transcription factors that control response to cellular context, 
and resistance to apoptosis. 
 In Chapter 4, we report our study of the role of Tbx18 in M15 and C2C12 cells. These 
two cell types are models for cells present in the developing urogenital system. M15 is derived 
from the mesonephric region of an E10.5 embryo (Ito et al. 2006). They are mesenchymal when 
sub-confluent and transition to epithelial upon confluence. In addition, they express Tbx18 at 
high levels (Ito et al. 2006; Larsson et al. 1995; Vuononvirta et al. 2009). C2C12 cells are used 
as a model for many types of study, but were chosen for this one because they have 
mesenchymal stem cell properties similar to the ones Tbx18 is naturally expressed in (Katagiri et 
al. 1994; Fux 2004; Lee et al. 2000). In these two cell types we performed TBX18 ChIP followed 
by hybridization to large promoter arrays, and we also performed Tbx18 siRNA-mediated 
knockdown followed by hybridization to expression arrays.  
 We found that the loss of Tbx18 significantly impacts the expression of a number of cell 
cycle actors and directors including E2f and Rb classically associated with cell cycle control 
(Chapter 4, Table 4.1). Also among the lists of differentially expressed genes with TBX18 
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binding sites adjacent to them are structural components of mitotic chromosomes, and cell cycle 
checkpoint factors such as Claspin, Cdk4, Cdc6, and Anaphase Promoting Complex. From these 
experiments within very different cellular contexts, it seems clear that Tbx18 is implicated in a 
network that is specific to mesenchymal cells in the developing embryo. In these mesenchymal 
cells, it appears to act on a set of powerful cell-cycle regulators to control proliferation. 
 The cell cycle regulators say little about how TBX18 may assist in the process of 
differentiation. However, the second class of putative TBX18 targets are themselves 
transcriptional regulators. Among the differentially expressed genes in our Tbx18 expression 
studies have been two hallmark regulators of urogenital development, the Wilms Tumor-
suppressor Wt1, and the SRY target in primary sex-determination Sox9. In the ureter, Tbx18, 
Sox9 and Wt1 act in a network to establish domains of the forming metanephric kidney and 
ureter. The boundary between Tbx18 in the ureter and Wt1 in the kidney is lost when Tbx18 is 
depleted (Airik et al. 2006). In the ureter mesenchyme, Tbx18 restricts Sox9 but also acts through 
Bmp4 to up-regulate Sox9 in the ureter epithelium (Airik et al. 2006; 2010; Trowe et al. 2012). 
Reciprocal signals under the control of epithelial Sox9 are Wnt7b and Wnt9b which act to 
maintain the adjacent mesenchymal Tbx18 expression (Bohnenpoll et al. 2013; Trowe et al. 
2012). Together these three factors create three domains: prospective kidney, ureter epithelium, 
and ureter stroma.  
Although it has not yet been demonstrated formally, our data suggest that a similar 
mechanism may operate in prostate. Sox9 expression, like in the ureter, is mostly expressed in 
the urogenital sinus epithelium (UGS-E), but is also detected in the UGS-M in lesser amounts. 
By contrast, Tbx18 is found in the UGS-M adjacent to the Sox9 expressing UGS-E cells. The role 
of Wt1 is less certain, as there is no published role for this gene in prostate development.  
However, our data open the exciting possibility that this well studied gene will also participate in 
a transcription factor network that is essential to prostate development. Our own data, as well as 
publicly listed in situ hybridization data (Diez-Roux et al. 2011) indicates that Wt1 is indeed 
expressed strongly in the UGS-M at its distal boundaries furthest from the UGS-E (not shown). 
How these genes interact in the UGS is a remaining question and will be a major focus of the 
Stubbs’ group efforts in the future. 
 In addition to being implicated in cell cycle control and cell-type specific transcription 
factors, Tbx18 is frequently associated with apoptosis. Rather, Tbx18 appears to resist apoptosis 
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in multiple in vivo studies (Bussen et al. 2004; Airik et al. 2006) including ours (Chapter 3). In 
the absence of Tbx18, cells submit to apoptosis resulting in reduced cell numbers and a smaller 
final organ. This general principle appears to hold true for the many diverse tissues in which 
Tbx18 is expressed. For example, in the somites, loss of TBX18 in the anterior somite half 
results in apoptosis of the supposed Tbx18-positive cells and leads to the migration of posterior 
somite cells into the anterior half. The result is compacted portions of the cervical and thoracic 
vertebrae with reduced axial skeleton length (Bussen et al. 2004). In the ureter, Tbx18 loss in 
prospective ureter smooth muscle cells results in their apoptosis, so that the stromal layer of the 
ureter is reduced in thickness and length (Airik et al. 2006). In our study of Tbx18 in the prostate 
(Chapter 3) we also observed very significant increases of apoptosis in the regions where Tbx18 
should be expressed in Tbx18-null animals. These studies, and the data in Chapter 4 argue that 
Tbx18 acts as a bulwark to apoptosis. It is unlikely that Tbx18 acts directly to control the 
expression of apoptotic genes as a regulator of programmed cell death is not obvious from our 
experiments. Rather, the apoptotic response we observe is probably a composite response to the 
lost control of several pro-proliferation factors. 
 Finally, one of the finer points in the study of Tbx18 is that in all cases examined, future 
Tbx18-expressing cells appear to be capable of migrating to the appropriate embryonic position 
(Nie et al. 2010; Airik et al. 2006; Bussen et al. 2004; Bohnenpoll et al. 2013; Trowe et al. 2008; 
Bolt et al. 2014). For example, in the somites and urogenital system, prospective Tbx18-
expressing cells migrate to the appropriate regions, even in Tbx18-null animals. Therefore, the 
locomotion and path-finding of these cells types is not dependent on Tbx18. However, when 
these cells reach their destination they require activation of Tbx18 to mediate the final stages of 
condensation and maintain appropriate signaling mechanisms. In the absence of Tbx18 they 
appear unresponsive to incoming signals and commit to death instead. 
 
The Future: 
Tbx18 prostate pathologies. 
 In Chapter 3 of this work, we demonstrate that reduced Tbx18 expression in the 
embryonic urogenital sinus mesenchyme (UGS-M) prevents proper formation of the ventral 
prostate lobe. Using the 12Gso allele, we were able to evaluate the impact of this on adult 
animals. What will be required next is a detailed assessment of the stages between birth and 
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adulthood, when the majority of the prostate is formed, so that we may investigate the 
intermediate steps of this phenotype progression. 
 In order to evaluate these intermediate steps, we need a method to systematically ablate 
Tbx18 expression during development in a controlled and tissue-specific fashion. The 12Gso 
prostate phenotype appears to be fully penetrant and is reproducible, but comes with its own set 
of challenges. The 12Gso translocation naturally causes reduced fertility due to assortment 
imbalances during gametogenesis. This reduces the number of 12Gso mutant conceptuses to 
1:16, not the usual 1:4 for standard null mutations. The focus on a male-specific tissue, the 
prostate, further reduces the number of usable embryos by half. Additionally, in the last few 
years, we have observed very few 12Gso mutants that survive beyond the first few days after 
birth. To overcome these obstacles, we are planning to use a conditional null allele of Tbx18 
using the Cre-Loxp system. We have obtained a “floxed” Tbx18 allele from our collaborator, 
Sylvia Evans (UCSD).  The main obstacle we face with this approach is identifying a UGS-M 
Cre that is activated early enough and in the same cell-type as Tbx18 to induce ablation of the 
floxed allele without also being co-expressed and epistatic in more essential organs such as the 
heart. Tamoxifen inducible systems are one possibility, but Tamoxifen has the adverse effect of 
causing urogenital defects when administered during gestation and can cause premature birth, 
also impacting animal viability (Iguchi et al. 1986; Cunha et al. 1987).  
 As such, we have recently decided to move forward on this project using a three-pronged 
approach. First, we are testing mice carrying a variety of Cre alleles to identify one that is 
expressed at the appropriate time in prostate, but not in other tissues during critical times in 
development. Second, we are in the process of establishing a Tetracycline-inducible Cre-
expressing line to allow “Tet-on” controlled inactivation of Tbx18. We will activate the Cre 
allele by feeding tetracycline analog, doxycycline (Dox), to pregnant females late in gestation, or 
to mothers nursing newborn litters, so that we may overcome the embryonic lethal phenotypes 
associated with early ablation of Tbx18. Third, we have begun to isolate and culture prostate 
organs from null mutant embryos using established methods (Staack et al. 2003) so that we may 
study prostate development during the first few days and weeks after birth -- the stages that 
Tbx18 ablation likely exerts its phenotypic control on ventral prostate development. 
 With these methods in place, we can systematically ask what cells take the position of 
Tbx18 cells after their apoptosis, and how does cell over-growth result from Tbx18 loss in the 
	   
 
 
110 
prostate, when a similar loss in other tissues results in tissue under-growth? For example, with 
the Tbx18GFP knock-in line of mice we can watch Tbx18 cells expressing GFP to monitor their 
fate and watch how the adjacent cells respond to their loss. At the developmental stages 
measured so far, the prostate rudiment is still confined within the urogenital sinus. What happens 
to these cells and Tbx18 expression during the stages where the prostate is growing and 
branching rapidly shortly after birth? Perhaps these studies will answer those questions. 
 
In vivo transcription targets and binding partners. 
 The remaining technical challenge to future study of Tbx18 is the difficulty obtaining 
tissue that is expressing it. Low quantities of TBX18 in a subset set of cells makes identification 
of ChIP targets difficult with current technologies. Isolating whole tissue contaminates the 
Tbx18-positive cells with additional chromatin and cellular material that makes it difficult to 
isolate the signal. Using a cell line overcomes these obstacles but introduces new problems such 
as aneuploidy and immortality, raising questions about the relevance of in vitro culture to in vivo 
biology. This is especially true with regard to Tbx18 that appears to be sensitive to dosage, 
background genetics, and has relevance to cell mortality.  
 We attempted to overcome these problems by using FACS to isolate Tbx18-positive cells 
from the UGS at E16.5 and E18.5. The number of cells recovered using this method is only 
around ten thousand cells per individual animal. This is a feasible number for genome-wide 
expression studies, but not for TBX18 ChIP. Standard ChIP-sequencing methods would require 
about 100 animals for a single experiment. Improvements in ChIP techniques have allowed for 
the reduction in the number of cells for some types of ChIP, such as histone ChIP, and new 
improvements to these methods may prove practical for transcription factor ChIP as well.  
 
Conclusion: 
 Tbx18 is an ancient and essential transcriptional regulator of mesenchymal development. 
Changes in Tbx18 expression produce disastrous malformations of several structures including 
the heart, vertebrae, inner ear, and urogenital system. This thesis describes how perturbations in 
Tbx18 expression influence the developing urogenital system. The major conclusions of this 
study are: The ECR1 enhancer drives Tbx18 expression during normal urogenital development 
and the 12Gso translocation sequesters ECR1 to the translocated chromosome T(4;9) preventing 
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it from activating Tbx18 during essential stages of urinary and prostate development. The 
primary impact of this dys-regulation is insufficient Tbx18 expression, which directly results in 
ureter and prostate malformations. The influence of the TBX18 protein is on genetic pathways 
involved in maintaining proliferation and differentiation, and Tbx18 mutants display 
insufficiencies related to the loss of these pathways. Finally, the premature loss of Tbx18 is 
frequently associated with apoptosis which is likely to be a general failure of proliferation rather 
than the direct stimulation of programmed cell death. Together, the consequence of these 
changes leads to improper formation of the tissue, which in some cases is lethal. The impact of 
Tbx18 abrogation is so strong that the lack of human diseases associated with this gene likely 
result from its absolute necessity during the formation of these organ systems. Future work will 
focus on the local network within which Tbx18 acts to affect proper formation and function of 
these organs. 
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